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Abstract 
Multiple sclerosis (MS) is an inflammatory disease that affects the central nervous 
system and is considered to be a T-cell mediated autoimmune disease. The “ideal” 
method in treating MS would be an antigen-specific therapy that does not require 
generalized immunosuppression. To date there are no definitive treatments for MS 
but there are several licensed therapies such as -interferon. Unfortunately the 
effect of interferon (IFN) is reduced by the development of neutralizing 
antibodies (NAbs) in up to 35% of MS patients within two years of starting 
treatment. 
 
An immunization schedule was developed in the BALB/c mice by subcutaneous 
administration of recombinant human IFN, and this resulted in development of high 
incidence of NAbs to the protein in the BALB/c model termed “NAbs model”. The 
mechanism of NAbs formation in this model is believed to be similar to that 
observed in IFN-treated MS patients with NAbs, which is as a result of an immune 
response to the protein. We elected to study NAbs in the context of IFN rather than 
MS directly to investigate the effects of antigen-specific tolerization strategies on 
the outcome of NAbs and indirectly on the outcome of IFN treatment in MS 
disease. 
 
The depletion of the immune cells triggers a reconstitution program that leads to 
renewal of the immune cell repertoire. Tolerance can be induced by intravenous 
administration of a protein. Within this window of reconstitution following depletion, 
it is hoped that the immune system can be manipulated to tolerate an otherwise 
foreign protein (human recombinant IFN). The tolerance strategy employed in this 
project was immune cell depletion using antibodies and mitoxantrone, followed by 
intravenous re-introduction of rhIFN. Tolerance was successfully induced in the 
NAbs model by intravenous administration of rhIFN, and further enhanced by 
immune cell depletion prior to intravenous administration of rhIFN. 
 
The BALB/c “NAbs model” offers a suitable model for use in investigating induction 
of tolerance to rhIFN following the formation of NAbs to the protein. The antigen of 
interest is known and the time to NAbs formation is also known. Tolerance induction 
can be monitored and investigated in this model. 
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Chapter 1 
1 Introduction 
 
1.1  Multiple sclerosis 
Multiple sclerosis (MS) is a chronic neurodegenerative disease and the major cause 
of neurological disability in young adults (Noseworthy et al., 2000). The immune 
system is thought to be a key player in the progression of the disease (Bruck, 
2005). The immunological attack is directed against the central nervous system 
(CNS), which is made up of the brain, spinal cord and the cranial nerves. MS is a 
major demyelinating disease which involves a breakdown of myelin (demyelination), 
the insulating sheath that surrounds nerve fibre extensions called axons, exposes 
these axons and thus affects the ability of neurons to transmit signals through the 
axon. MS affects about 2.5 million individuals worldwide with an average age of 
onset between 20 and 40 years (Compston et al., 2002). 
 
To date, allocating the cause of MS disease to a single element has been elusive. It 
is plausible that susceptibility to disease is as a result of several interacting factors 
including genetic factors, age and environmental factors such as lifestyle, climate 
and vitamin D (Hauser et al., 2006). Several bacterial and viral triggers have been 
proposed as causes for MS; however, so far conclusive evidence is missing. One 
such candidate is Epstein-Barr virus (EBV), which has been linked to MS (Ascherio 
et al., 2007; Jilek et al., 2008). 100% of MS patients have been infected with EBV in 
comparison with 95.8% of age-matched healthy controls and the risk of developing 
MS is increased in individuals who develop infectious mononucleosis (acute EBV 
infection) (Giovannoni et al., 2006). The MS risk associated with infectious 
mononucleosis appears to persist throughout life. It has been suggested that EBV 
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infected B cells infiltrate the brain resulting in damage that lead to the initiation of 
MS disease (Serafini et al., 2007). These observations have not been reproduced 
(Peferoen et al., 2009; Willis et al., 2009) as a result the role of EBV in MS 
pathology remains to be ascertained.   
 
There are geographic differences in the prevalence of MS; the incidence of MS is 
highest in temperate regions including North America, Northern Europe, Southern 
Australia and New Zealand, with a decrease closer to the equator which is 
coincidental with annual sunlight exposure (Hayes et al., 1997). Exposure to 
sunlight and UV has an effect on vitamin D synthesis and vitamin D has been 
suggested to have a positive role in MS (Pierrot-Deseilligny, 2009). Vitamin D is 
thought to be an immunomodulatory agent and has its effects on HLA gene 
expression by interacting with HLA-DRB1 promoter region, this region is preserved 
in MS associated with DRB1*1501 allele (Ramagopalan et al., 2009). There is an 
increasing incidence of MS in females, approximately two thirds are female 
(Reingold, 2002). Age may also play a role in incidence, exposure to high or low-
risk areas before age of early adulthood appears to play a major role in the 
incidence of MS. Once the high- or low-risks has been established in early 
adulthood, migration appears to play a smaller role in incidence of MS (Waksman, 
1995).  
 
A genetic association exists between certain major histocompatibility complexes 
(MHC) and the risk of developing MS. An association has been reported between 
HLA-DR2 (DRB1*1501, DRB5*0101, DQB1*0602) class II antigens and MS in 
Caucasian populations of northern and central Europe (Chao et al., 2008; Lincoln et 
al., 2005; Olerup et al., 1991; Spurkland et al., 1991). HLA-DR2 carries a fourfold 
relative risk for northern European Caucasians (Oksenberg et al., 1993). 
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DRB1*0401 and DRB1*0301 are overrepresented in MS patients from southern 
Europe (Fogdell-Hahn et al., 2000). Genome-wide association studies have recently 
been carried out and have revealed a number of loci that may be associated with 
the disease including IL2 receptor (Alcina et al., 2009) and IL7 receptor (Lundmark 
et al., 2007) and now there have been over 150 non-HLA gene regions linked to 
susceptibility to MS. (Sawcer et al., 2011). Genetics plays a role in disease as is 
seen in the incidence rate in monozygotic twins (~30%) in comparison with 
dizygotic twins (~5%) (Compston et al., 2008). The incidence is relatively low 
implying that other factors may also be at play in susceptibility to the disease 
(Sadovnick et al., 1993).  
 
1.1.1 Clinical  
The diagnosis of MS is usually clarified by the ‘McDonald Criteria’ which requires 
dissemination of the disease process in both time and space, and exclusion of other 
causes (McDonald et al., 2001). Clinical diagnosis is made using magnetic 
resonance imaging (MRI) scan and typically requires two relapses due to lesions in 
separate locations and different times (Fisniku et al., 2008). A definitive diagnosis 
can take months or even years to establish with confidence in some cases 
(McDonald et al., 2001; Nielsen et al., 2007).  
Individuals with MS typically experience one of a number of clinical courses of the 
disease, which may be mild, moderate or severe. Approximately 15% of MS 
patients experience benign MS in which case the patient completely recovers from 
episodes of the disease; the disease does not progress with time and there is no 
permanent disability (Ramsaransing et al., 2006). Primary progressive MS (PPMS) is 
characterized by slow progression from the onset of disease in approximately 15% 
of MS patients, with steady worsening of disability and usually clinically develops at 
a later age (Andersson et al., 1999). The most common clinical course of MS is 
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relapsing-remitting MS which affects approximately 85% of patients. There are 
episodes of exacerbation of the disease (relapse) from which there is partial or total 
recovery and remission (Noseworthy et al., 2000). As part of a relapse the patient 
may develop new symptoms or a worsening of pre-existing symptoms. Due to 
accumulation of damage in the central nervous system, the disease deteriorates to 
secondary progressive MS (SPMS). 
Various neurological symptoms are present in MS patients depending on the part of 
the central nervous system involved in the disease. Neurological symptoms include 
weakness in limbs, limb tremor, optical neuritis, pain and spasms (Hauser et al., 
2006). 
 
1.1.2 Immunology and Pathology 
The heterogeneous and unpredictable nature of MS adds to the complexity of 
determining the sequence of events leading to the cause of MS disease (McFarland 
et al., 2007). MS appears to be a T cell-mediated disease and the immune system a 
key player in the progression of the disease (Bruck, 2005). The immunological 
attack is directed against the central nervous system (CNS) which is usually 
associated with blood:brain barrier (BBB) dysfunction resulting in infiltration of 
mononuclear cells. Inflammatory events ultimately lead to neurological damage 
including demyelination and axonal loss (Weiner, 2004).  
 
The antigen involved in initiating MS disease remains to be determined. A typical 
response to an antigen is focused on one or more dominant epitopes. With epitope 
spreading, there is diversification of the previously dominant epitopes which 
involves previously subdominant epitopes now becoming more dominant in the 
immune responses elicited. A spread of multiple antigenic determinants has been 
reported in MS patients over the time course of the disease. Patients with 
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established disease recognize more myelin epitopes than patients with recent-onset 
disease (T cell responses in MS broadens with time) and is thus implicated in the 
ongoing pathogenic process (Davies et al., 2005). Due to evidence of the 
involvement of myelin proteins in MS, altered peptide ligands (APL) of these 
proteins have been investigated as potential therapy in the disease. APLs are 
analogs of immunogenic peptides in which there have been changes in the T cell 
receptor contact sites. Some trials with APL have shown the potential of APL in MS 
therapy (Bielekova et al., 2000) but other trials have seen exacerbation of disease 
(Martin et al., 2001; Vergelli et al., 1996), and might even suggest that myelin may 
be the autoantigen in MS.  
 
The factor or antigen and mechanism involved in MS is elusive but once initiated, it 
appears to activate autoreactive T cells in the periphery and leads to dysfunction of 
the BBB. Evidence of BBB disruption has been shown using gadolinium enhanced 
MRI (Alnemri et al., 1996). Adhesion molecules on the surface of activated T cells 
such as very late activation molecule-4 (VLA-4/CD49d) bind to its ligand vascular 
cell adhesion molecule-1 found on brain epithelium (Hemler, 1990) and this enables 
T cells cross the BBB. It is thought that once these autoreactive T cells (CD4+) 
cross the BBB and come in contact with autoantigens, an inflammatory cascade of 
events is initiated. T cell and antibody-mediated responses to various myelin 
proteins and activated membrane attack complexes of complement in the CNS have 
been described (Trbojevic-Cepe et al., 1998). Some target antigens for these T cells 
include myelin basic protein (MBP), proteolipid protein (PLP), myelin 
oligodendrocyte glycoprotein (MOG), myelin associated glycoprotein (MAG) and B 
crystallin (Pender et al., 2007; van Sechel et al., 1999). CD4+ T cell initiated 
inflammation leads to stimulation of B cells, other T cells, macrophages and 
microglia, with amplified responses to pro-inflammatory molecules such as 
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chemokines, cytokines and adhesion molecules (Hjelmström et al., 1998). These 
pro-inflammatory cytokines promote BBB dysfunction by increasing permeability of 
the BBB and recruitment of other immune cells including T cells (Th1, Th2 and Th17 
CD4+ cells), CD8 T cells natural killer (NK) cells and macrophages, into the CNS. 
These activated cells form free radical species such as nitric oxide which have been 
shown to kill oligodendrocytes and motor neurons (Bishop et al., 2009). This 
complex array of immunological events leads to demyelination, spontaneous 
remyelination and loss of axons (Neumann, 2003). Loss of myelin (demyelination) 
and oligodendrocytes, termed lesions are as a result of infiltration immune cells into 
the CNS and is the pathological hallmark of MS. Lesions can be found in the brain 
stem, cerebellum, optical nerves and in the spinal cord (Noseworthy et al., 2000). 
Remyelination occurs spontaneously following loss of myelin, but the capacity is 
eventually overwhelmed (Franklin et al., 2008). Demyelination leads to exposure 
and loss of axons and thus affects neurotransmission (Bjartmar et al., 2003), 
leading to development of additional symptoms such as limb tremors, fatigue and 
pain (Compston et al., 2002).  
 
1.1.3 Current treatments 
To date there are no definitive treatments which cure MS, but there are several 
therapies (which generally act as immunomodulators or immunosuppressive agents) 
for reducing relapse rate and severity of clinical outcome of early disease 
(Confavreux et al., 2004).  These include Interferon-beta, glatiramer acetate, 
mitoxantrone, corticosteroids and several monoclonal antibodies including 
natalizumab (an anti-VLA4 monoclonal antibody). Some of these therapies however 
have adverse side-effects and are only moderately effective at reducing severity of 
disease outcome (Thrower, 2009). 
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Glatiramer acetate (Copaxone™, Teva Pharmaceuticals) is a synthetic amino acid 
copolymer of L-alanine, L-glutamic acid, L-lysine and L-tyrosine, an analogue for 
myelin basic protein (MBP). It reduces the frequency of neurological attacks when 
used in the treatment of relapsing-remitting MS (Khan et al., 2001). The mode of 
action remains unclear but it is thought that Glatiramer acetate acts as an altered 
peptide ligand (APL) as it may cross-react with MBP and other myelin proteins and 
is thought to inhibit MBP-specific T cells, which may be important in MS (Dhib-
Jalbut, 2003). 
 
Corticosteroids are currently being used to treat relapses in MS patients. They are 
immunosuppressive in action, they alter the expression of adhesion molecules and 
vascular permeability (Tischner et al., 2007). Steroids have been shown to speed up 
recovery from a relapse or disability (Brusaferri et al., 2000). However, long term 
use of steroids has side effects and has moderate effect on relapse rate or outcome 
of disease progression. (Miller et al., 2000).  
 
Mitoxantrone (Novantrone®, Merck-Serono) is an anthracenedione which acts by 
intercalating into the DNA molecule, it also interferes with RNA, and uncoiling and 
repair of damaged DNA by inhibiting topoisomerase II enzyme (Fox, 2006).  
Mitoxantrone acts in a dose-dependent manner and is a potent immunosuppressive 
agent which inhibits in vivo induced proliferative response (Baker et al., 1992). 
Clinical trials data suggest efficacy of mitoxantrone in reducing relapses and slowing 
disease progression in relapsing-remitting and secondary progressive MS 
(Debouverie et al., 2007; Le Page et al., 2008). The action of mitoxantrone is by 
non-specific immunosuppression of the immune system and cardiotoxicity is one of 
its serious side effects (Ghalie et al., 2002). 
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FTY720 (Fingolimod, Gilenya™) is a sphingosine-1-phosphate receptor antagonist 
and inhibits the migration of lymphocytes from secondary lymphoid organs to the 
periphery (Brinkmann et al., 2004). Fingolimod has been shown to reduce relapse 
rate and the risk of disability progression in RRMS (Kappos et al., 2010). As with 
some other immunosuppressive agents, Fingolimod has several side effects 
including increased risk of infection by opportunistic bacteria/viruses and 
development of tumours (Cohen et al., 2011). 
 
Cladribine (Movectro™) is a purine nucleoside analogue. Its activated form, 
Cladribine triphosphate, disrupts DNA synthesis and repair and causes accumulation 
of deoxynucleotides (Brousil et al., 2006). Initial clinical trials of Cladribine showed 
a significant reduction in relapse rates (Giovannoni et al., 2010), however the drug 
has now been withdrawn from the market. 
 
Several monoclonal antibodies (mAb) are being developed or are currently used in 
the treatment of MS. Natalizumab (Tysabri™) is a humanized monoclonal antibody 
(mAb) that binds to 4 chain of the 41 integrin or very-late-antigen 4 (VLA4) 
which is expressed on all leucocytes except neutrophils. VLA binds to vascular cell 
adhesion molecule (VCAM) which is found on and upregulated in endothelial cells 
during inflammation (Luster et al., 2005). Binding of Natalizumab® to VLA4 blocks 
it binding to VCAM thereby inhibiting the extravasation of leukocytes across the 
endothelium to target organs (Johnson, 2007). Natalizumab® was the first mAb to 
be approved in Europe and the USA for the treatment of relapsing-remitting MS 
(Miller et al., 2003). 
 
Alemtuzumab® (CAMPATH-1H) is a humanized mAb that binds to CD52 which is 
expressed on a number of cells of the immune system; binding results in the 
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depletion of the targeted cells (Moreau et al., 1994). Alemtuzumab® therapy 
results in an impressive reduction in MS exacerbation, but consistent with effects of 
other immunosuppressive agents, it fails to inhibit progressive MS (Coles et al., 
2008).  
 
Rituximab® is a chimeric mouse-human mAb that is targeted against CD20 
expressed on B cells. Rituximab® depletes a subpopulation of B cells (pre-B and 
mature B cells) without affecting antibody production and secretion (Petereit et al., 
2008). Rituximab® has been shown to reduce relapse rate by about 50% in 
relapsing-remitting MS (Bar-Or et al., 2008). 
 
1.2 Interferon-beta treatment 
Type I interferons (IFNs) include IFN, IFN, IFN and IFN, and are produced by a 
number of cell types in response to viral infections (Malmgaard et al., 2003); they 
are capable of limiting the replication and spread of viruses during an infection 
(Bogdan, 2000). IFNs signal through receptors found on many cell surfaces (Zhang 
et al., 2008). The type I IFN receptor (IFNAR) is made up of two subunits IFNAR1 
and IFNAR2 which are found on target cells; binding of IFN to the receptor results 
in signalling through the Janus kinase to induce certain genes, the products of which 
makes the target cell resistant to viral replication (Muller et al., 1994). Mx proteins 
(MxA and MxB) are induced by type I IFNs, upon stimulation they accumulate in the 
cytoplasm of cells; MxA has been shown to have anti-viral properties (Haller et al., 
2002).  
Interferon-beta (IFN) is a licensed immune modifying therapy; there are two 
forms: IFN-1a and IFN-1b. IFN-1a (Avonex®, Rebif®) is produced in Chinese 
hamster ovary cells and its amino acid sequence is identical to that of the natural 
IFN(Kagawa et al., 1988a). IFN-1b (Betaferon®) on the other hand is produced 
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in Escherichia coli and its sequence is slightly different to the natural sequence; the 
cysteine residue is substituted with serine at position 17 and it lacks methionine-1 
(McCullagh et al., 1983). As IFN-1b is produced in E. coli it is non-glycosylated. 
The action of IFN in MS is unknown. Although IFNs have anti-viral activity, it is 
thought that IFN acts on immune cells by modulating their actions via cytokine 
production, skewing their response from an IFN producing Th1 response towards a 
Th2 response (Hartung et al., 2004). IFN has the ability to reduce proliferation of 
lymphocytes by decreasing expression of activation markers such as IL2 receptors 
and IL10 an immunosuppressive cytokine, and thereby reduces the migration of 
activated inflammatory cells through the blood brain barrier (BBB) into the CNS 
(Noronha et al., 1993; Rudick et al., 1998). IFN has been shown to reduce relapse 
rates in relapsing-remitting MS and prolong the time to confirmed progression in 
secondary progressive MS (Group, 1993).   
 
1.2.1 Anti-interferon-beta antibodies 
Naturally occurring proteins are usually tolerated by the body and these proteins do 
not generally invoke an immune response. When these naturally occurring proteins 
are synthesised or genetically modified, they may have changes made to their 
structure which may then lead to a loss of immune tolerance to the protein when 
administered. Due to the loss of tolerance to the protein, antibodies may be 
generated which are either binding antibodies (BAbs) or neutralizing antibodies 
(NAbs). Neutralizing antibodies generally bind to the protein and prevents the 
binding of the protein to its receptor and thus inhibits the action or bioavailability of 
the protein. BAbs do not significantly affect the action of proteins, but may act as 
carriers or may increase the elimination of the proteins. 
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Due to the difference in structure of IFN-1a and IFN-1b from the natural protein 
(Kagawa et al., 1988b; McCullagh et al., 1983), IFN formulation, chronic 
administration of large amounts of protein and route of delivery, antibodies to these 
proteins develop over treatment time (Hartung et al., 2007). Some IFN-specific 
antibodies termed BAbs bind IFN but do not significantly affect the binding of IFN 
to its receptor or the activity of the protein. BAbs may form immune complexes with 
IFN which are cleared from the circulation (Perini et al., 2001). On the other hand, 
NAbs bind IFN and reduce its bioavailability by blocking the binding of IFN to its 
receptor mainly found on immune cells (Malucchi et al., 2004).  
Varying incidences of BAbs (10 to 90%) and NAbs (2 to 47%) have been reported in 
MS patients (Bertolotto et al., 2004; Giovannoni et al., 2002). Approximately 35% 
of MS patients develop NAbs to IFN within 2 years of starting treatment; of these 
patients, approximately 50% will revert to a negative NAbs status. Persistently high 
positive titres of NAbs have been associated with a greater number of relapses or 
more progression in MS patients (Francis et al., 2005; Sorensen et al., 2003).  
 
1.2.2 Clinical and biological significance of anti-IFN antibodies 
The clinical significance of NAbs to IFN in MS patients is an ongoing debate and 
several studies have been done to investigate the significance on relapse rate and 
clinical outcome. 
In a study comparing the efficacy of IFN with Copaxone (BECOME Study), it was 
shown that patients with high levels of NAbs had diminished reduction in enhancing 
lesions on MRI and this was also associated with reduction in bioactivity of IFN 
(Pachner et al., 2009). Development of NAbs to Rebif in the PRISMS study led to a 
loss of significant reduction in relapse rate and MRI activity (PRISMS-4., 2001). In a 
longitudinal study, it was described that NAbs positive patients had fewer relapses 
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in the first 6 months of treatment when compared with NAbs negative patients, but 
then after 6 months they experience higher relapse rates (Sorensen et al., 2005).  
There is a faster development of NAbs in IFN-1b-treated patients in comparison 
with IFN-1a-treated patients; a higher protein dose of IFN-1b is used by patients 
and may be responsible for this (Ross et al., 2000). IFN-1b is also a mutated 
protein, has reduced bioactivity and is non-glycosylated that may increase its 
immunogenicity. In a study, a higher proportion of NAbs positive patients were 
observed in the high dose Avonex group and these patients had a higher relapse 
rate within 1-4 years of treatment (Kappos et al., 2005). 
 
NAbs to IFN appears to develop within 2 years of treatment but the clinical impact 
may not be felt until sometime later, this highlights the need for more long term 
follow-up for NAbs positive patients. Over time, it has been shown that 
approximately 30% of NAbs positive patients revert to a negative status mainly in 
patients with low NAbs titres and those treated with IFN-1b (Sorensen et al., 
2005). 
  
1.3 Immunological tolerance 
In a healthy immune system, discrimination between self and non-self-antigens 
usually occurs, resulting in a balance. This is termed immune tolerance which is the 
ability of the immune system to distinguish self from non-self and harmful from 
harmless molecules. Tolerance is also the inability to mount an immune response to 
a subsequent rechallenge with the same antigen. The route of antigen introduction 
is critical in determining the outcome of an immune response. Intravenous and 
mucosal administration of antigen for example, favours the induction of tolerance to 
the antigen (Verbeek et al., 2007). Tolerance is a state of non-responsive in the 
presence of an antigen, in a healthy immune system these are generally self 
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antigens. There are two coordinated processes referred to as central and peripheral 
tolerance which results in functional tolerance to self-antigens. These processes 
include the deletion of autoreactive lymphocytes in the central lymphoid organs 
during lymphocyte maturation; and suppression of autoreactive lymphocytes in the 
periphery that may have escaped elimination. 
 
 
1.3.1 Central tolerance 
Central tolerance is the process by which lymphocytes reactive to self-antigen are 
largely eliminated during development in the primary lymphoid organs. The main 
method of elimination is by deletion through negative selection. In the case of T 
cells, central tolerance occurs when the bulk of self-reactive T cells are deleted 
during thymic development. T cell development occurs in the thymus, were 
rearrangement of the T cell receptor (TCR) genes occurs leading to the diversity of T 
cell population. T cells undergo TCR - and - locus rearrangement and are 
characterized as double positive (CD4+/CD8+). These double positive cells either 
survive or are eliminated depending on the interaction of the TCR with self-antigen-
MHC complex. TCR rearrangement (receptor editing) may occur in these cells which 
may increase self-MHC restriction (McGargill et al., 2000). A large proportion of 
these double positive cells do not display any specificity for a major 
histocompatibility complex (MHC) ligand and undergo apoptosis or “death by 
neglect” (Surh et al., 1994). During intrathymic development, a small proportion of 
double positive T cells with TCR that bind with low avidity to antigen loaded in MHC 
molecules results in the maturation to the single positive stage- CD4+/8- or CD4-
/8+ (Starr et al., 2003). T cells with TCR that bind to self-antigen loaded on MHC 
molecules undergo one of 2 selections. T cells with low to medium affinity for self-
antigen receive survival signals that ligate the TCR and leads to survival of these T 
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cells and is termed positive selection (Klein et al., 2009). Another selection process 
termed negative selection leads to apoptosis of T cells with TCR with strong affinity 
for self-antigen, strong enough to have the potential of being autoimmune disease 
mediators. These cells are eliminated by apoptosis in the absence of costimulation 
and are usually Fas-dependent (Kishimoto et al., 1998). This negative selection 
process is aided by the transcription factor Aire (autoimmune regulator). Aire is an 
autoimmune regulator gene and facilitates the thymic expression of tissue specific 
antigens by thymic epithelial cells (Anderson et al., 2011). Several studies have 
shown that Aire-expressing cells are involved in T cell generation and negative 
selection (Perry et al., 2014). The generation of particular T cells (such as T reg) at 
specific times during T cell development prevents autoimmunity (Tanaka and 
Sakaguchi, 2015). Anomalies in T cell generation and negative selection, and an 
imbalance between T regulatory cells and self-reactive T cells can lead to or 
predispose to, autoimmune disease. The ideal outcome of these selection processes 
would be a T cell repertoire with TCRs that may bind to self-MHC molecules but are 
unresponsive to self-antigen (Griesemer et al., 2010).  
 
B cell development occurs in the bone marrow (Osmond, 1990). Primary 
development of B cells is defined by the re-arrangement and expression of antigen 
receptor composed of immunoglobulin (Ig) light chain and heavy chain genes.  The 
arrangement of the B cell receptor confers a high degree of antigen specificity and 
this influences clonal selection (Riolink et al., 1991). Rearrangement of the heavy 
chain occurs in pro-B cells where D and J elements are ligated resulting in functional 
heavy chain protein synthesis (Kitamura et al., 1992). These pre-B cells then 
undergo light chain rearrangement and express IgM on their surface. The antigen 
receptors displayed on the surface of pre-B cells then interact with antigen leading 
to clonal selection (for activation or elimination). Self-reactive B cells are deleted in 
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the bone marrow by clonal deletion, receptor editing and anergy (Wardemann et al., 
2003). Some autoreactive B cells successfully rearrange their light chain resulting in 
altered specificity and survival (Tiegs et al., 2011). The surviving B cells leave the 
bone marrow for the periphery; these B cells are immature and have IgM expressed 
on their cell surface. B cells that survive negative selection differentiate to become 
mature B cells (naive cells) that express IgD, IgM and other proteins such as B220 
in mice. B220 is expressed in all stages of B cell development in the mouse. The 
final stages of development of B cells take place in the spleen (Loder et al., 1999); 
B cells undergo antigen-dependent differentiation into antibody-secreting and/or 
memory B cells. Developing B cells that bind weakly to self-antigen survive through 
positive selection and their Ig undergoes rearrangement (Levine et al., 2000). 
 
1.3.2 Peripheral tolerance 
It has been reported that some self-reactive T cells may escape into the periphery 
(Liu et al., 1995). These “escaped” cells may be dangerous as they can potentially 
be recruited and activated resulting in an autoimmune response. To monitor such 
potentially dangerous cells, a mechanism termed peripheral tolerance is in place to 
prevent these cells from orchestrating an autoimmune attack (Kisielow et al., 1988; 
Walker et al., 2002). Clones of cells that respond to self-antigen are generally 
deleted preventing the proliferation of these cells in response to the antigen 
(McCaughtry et al., 2008). The key mechanisms that maintain tolerance in the 
periphery include clonal deletion, anergy, ignorance, and regulation. Most cells of 
the immune system require two signals for the activation of the cells; T cells for 
instance require a signal through the TCR as well as a second co-stimulatory 
activation signal(s). The absence of the second activation signal leads to the 
induction of cell death or anergy (a state of unresponsiveness to antigen) and 
robust tolerance (Chen, 2004). One important costimulatory signal in T cell 
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activation results from the interaction of CD28 receptor on T cells and its ligands 
(CD80 and CD86) on antigen presenting cells (APC) (Sharpe et al., 2002). This 
interaction leads to activation of T cells and anti-CD28 antibody was used in this 
project as a co-stimulatory molecule for cytokine production. Another costimulatory 
interaction is the binding of CD154 on activated T cells and CD40 on APCs (Croft, 
2003). Blocking of these costimulatory signals has been shown to induce tolerance 
in allografts in rodents. (Foster et al., 2003; Honey et al., 1999); and regulatory T 
cells may play a role in the establishment of early tolerance (Verbinnen et al., 
2008). 
 
Cell activation is delicately counterbalanced by the production of regulatory cells 
some of which appear to be inducible in the periphery; these regulatory T cells (T 
regs), are thought to be central to peripheral tolerance through their suppressive 
function (Bach, 2003). T regs suppress several cell types including CD4+ helper 
cells, CD8+ cytotoxic T lymphocytes, antibody production by B cells and APC 
function (Eddahri et al., 2006; Mempel et al., 2006; Taams et al., 2000). In a 
subset of T regs known as CD25high-FoxP3+ T regs, there is an upregulation of 
forkshead transcription factor (Foxp3) following activation, expression of FoxP3 does 
not always correlate with the suppressive function (Tran et al., 2007). Another 
subset of T regs is the type 1 T regs (Tr1) that are suppressive through the 
production of high levels of IL10 and transforming grown factor beta (TGF) (Groux 
et al., 1997). Tr1 cells do not express Foxp3 (Vieira et al., 2004). A third subset of T 
regs is known as Th3 cells, these are regulatory cells that are a result of conversion 
of naive CD4 T cells to inducible T regs by TGF(Chen et al., 2003). Of these 3 
regulatory T cells, FoxP3+ T regs are the best studied and are thought to keep 
potentially autoreactive T cells unresponsive in the periphery (Sakaguchi et al., 
2008). Most T regs develop in the thymus with a few induced in the periphery from 
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naïve CD4 T cell pool (Fontenot et al., 2005; Shevach et al., 2008).  T regs 
produced by the thymus have TCRs on their surface with increased affinity to self-
antigen and this could be as a result of positive thymic selection for self-antigen or 
by clonal expansion of autoreactive clones in the periphery (Hsieh et al., 2004). In 
addition, there are T regs reactive to foreign antigen and they expand and function 
in an antigen-dependent manner (Verma et al., 2009). Tolerance interventions may 
boost the numbers and functions of T regs and/or inhibit the activation of naive T 
cells by co-stimulatory blockage (St Clair et al., 2007). 
 
1.3.3 Tolerance induction 
A breakdown in tolerance can lead to an immune response to an antigen that would 
otherwise not elicit a response. A breakdown in tolerance to self-antigen for 
example is an underlying thread in many autoimmune diseases; and allergic 
diseases involve an impaired tolerance to otherwise harmless molecules. In MS, 
breaking of tolerance to auto-antigens e.g. myelin basic proteins, is thought to be of 
pathogenic relevance in the clinical outcome (such as lesion distribution) of the 
disease (Greer et al., 2008). Induction of tolerance on the other hand is a deliberate 
process of inducing tolerance to an antigen where a response has been established 
or a response is likely. Many strategies for induction of tolerance have been 
reported in naive immune cells including oral and intravenous route of immunization 
and high or low dose antigen. 
 
Oral therapies have been studied in the treatment of IgE-mediated food allergies 
such as milk, peanuts and eggs. Cells of the mucosa-associated lymphoid system 
play an important role in lymphocyte development and antigen presentation. The 
mucosa-associated lymphoid system continually undergo antigenic stimulation 
resulting mostly in oral tolerance rather than inflammatory immune reactions (Faria 
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et al., 2006). A breakdown of this immune responses or a shift of the immune 
responses from oral tolerance to immune reaction could lead to autoimmune or 
allergic diseases.  Induction of oral tolerance is mainly achieved by prior oral 
administration of the protein which leads to suppression of humoral and cellular 
responses upon subsequent exposure to the protein (Faria et al., 2006). Oral 
administration of antigens also leads to induction of regulatory T cells (Weiner et al., 
2011). One oral therapy for instance involves the ingestion of small amounts of the 
protein with increased doses over time leading to the exposure of the protein to 
tolerogenic APCs in the oral mucosa and these may potentially enhance the 
induction of tolerance to the protein (Allam et al., 2008).  
 
Intravenous administration of antigen has been shown to induce tolerance in naïve T 
cells by apoptosis or anergy; the major mechanism being antigen presentation 
without co-stimulation (Liblau et al., 1996). Memory T cells have less stringent 
activation requirements than naive cells with reduced and in some cases no co-
stimulation required, as such it can be difficult to induce tolerance in mice with 
memory T cells (Valujskikh, 2006). Tolerance has been successfully induced in 
memory T cells in mice by administration of soluble antigen (Hayashi et al., 2002). 
Tolerance has also been induced by i.v. administration in established memory 
responses in haemophilia patients. Neutralizing antibodies to factor VIII (FVIII) 
develop over time in haemophilia A patients treated with FVIII products; this leads to 
inhibition of the products.  Immune tolerance to FVIII has been achieved in these 
patients by continuous infusion of recombinant FVIII without this most haemophilia 
patients may have limited alternative treatment (Tamura et al., 2006). In a mouse 
model of this condition, it was shown that high doses of i.v. FVIII led to the inhibition 
of FVIII-specific memory B cells (Hausl et al., 2005). On the other hand, i.v. route of 
antigen introduction has been shown to boost antibody responses and i.v. MOG 
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stimulated a B cell response leading to the exacerbation of chronic EAE in marmosets 
(Genain et al., 1996). In another study, the effect of the route of treatment with 
IFNb in a transgenic mice showed that i.v. treatment lead to the production of anti-
IFNb antibodies and this was comparable with the i.m., i.p. and subcutaneous route 
of administration of the drug (Kijanka et al., 2013). In a human study, IFN was 
repeatedly given i.v. in NAbs positive patients and this increased the bioavailability of 
the drug but did not appear to induce tolerance to IFN (Hegen et al., 2014). Antigen 
administration by i.v. has most consistently induced antigen-specific tolerance in 
established cell-mediated autoimmunity or hypersensitivity. The main mechanisms 
involved in i.v. induction of tolerance are clonal deletion, induction of regulatory T 
cells and anergy of antigen-specific T cells (Jacobs et al., 1994). Variations to the i.v. 
method of tolerance induction have also been reported in animal models including 
cross-linking antigen (peptides) to splenocytes with 1-ethyl-3-(3-
dimethylaminopropyl)-carbodiimide (ECDI) a cross-linking agent. Cross-linking of 
splenocytes with antigens induced an antigen-specific tolerance in the EAE model 
which led to prevention and treatment of disease in this model; tolerance was long-
lasting and improved in comparison with soluble peptides (Turley et al., 2007). 
Microparticles have also been used in prevention and treatment of EAE. 
Microparticles delays the release of antigens and this induced long-term T cell 
tolerance in mice with EAE, preventing the onset and modifying the course of the 
disease in these mice (Getts et al., 2012). Another variation to i.v. tolerance 
induction is by the depletion of cell subsets prior to i.v. introduction of antigen. In 
the EAE model, it has previously been shown that reduction of cell subset pools (CD4 
T cell depletion) prior to tolerance induction produced a robust unresponsiveness in 
established EAE disease (Pryce et al., 2005). 
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1.4 Aims of this project 
The aim of this project is to develop a neutralizing antibody “NAbs” mouse model 
against recombinant human interferon beta for the study of tolerance induction, 
which is relevant for IFN-treated multiple sclerosis patients that have developed 
neutralizing antibodies.  
 
The objectives of the project are: 
1. To develop neutralizing antibodies to recombinant human interferon beta in a 
mouse model that can be used to study the induction of tolerance (chapter 3). 
 
2. To develop a strategy for the depletion of cell subsets in naïve mice and 
NAbs mouse model using CD4+ and CD20+ depleting antibodies and mitoxantrone 
(chapter 4). 
 
3. To develop a tolerization strategy in the NAbs mouse model by intravenously 
re-introducing rhIFN (chapter 5). 
 
4. To further develop the tolerization strategy in the NAbs mouse model by 
depletion of cell subsets prior to intravenous re-introduction rhIFN (chapter 5). 
 
5. To compare the effectiveness of depletion strategies in the well-established 
EAE model (chapter 6). 
 
Achieving these objectives will result in the NAbs model being used to study 
different tolerization strategies against the development of neutralizing antibodies to 
rhIFN. These tolerization strategies can then be investigated in IFN-treated MS 
patients with NAbs to the protein. 
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Chapter 2 
2 Materials and Methods 
2.1 Animals 
Mice were purchased and maintained on a 12h:12h light:dark cycle and received 
food and water ad libitum. All procedures were approved following ethical review 
processes in accordance with UK legislation (Animals (Scientific Procedures) Acts 
1986). 
 
2.1.1 Biozzi ABH mice 
Adult male and female (6-8 weeks) Biozzi ABH mice were used and were purchased 
from Harlan UK Ltd (Bicester, UK). These mice were used for the EAE studies and 
preliminary NAbs studies. 
 
2.1.2 BALB/c mice 
Adult male and female (9-20 weeks) BALB/c mice were used and were purchased 
from Charles Rivers (Margate, Kent). These mice were used in most of the studies. 
 
2.2 Solutions and Media preparations 
2.2.1 Complete RPMI culture medium 
Component  Final concentration Volume (ml) 
RPMI - 450 
Heat-inactivated FBS 10% 50 
Penicillin 100 units 2.5 
Streptomycin 100 g 2.5 
2- beta-
mercaptoethanol 
5 mM 5 
 
Table 2.1:  Preparation of complete RPMI culture medium. RPMI-1640 
(Invitrogen, Paisley, UK), heat-inactivated foetal calf serum (Invitrogen, Paisley, 
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UK), 5 mM beta-mercaptoethanol (Sigma-Aldrich, Poole, UK) and 
penicillin/streptomycin (Sigma-Aldrich, Poole, UK). 
2.2.2 FACS Buffer 
Calcium and magnesium- free phosphate buffered saline (Invitrogen, Paisley, UK) 
was supplemented with 2% heat-inactivated foetal calf serum (Invitrogen, Paisley, 
UK). 
 
2.2.3 Lysis buffer 
Component  Concentration Weight (g) Volume (ml) 
Ammonium chloride 15 mM  4.14 - 
Potassium bicarbonate 10 mM 0.5 - 
EDTA 20 mM 18.62 2.5 
Distilled H2O - - 500 
 
Table 2.2: Preparation of lysis buffer. Ammonium chloride, Potassium 
bicarbonate, EDTA solution (Sigma-Aldrich, Poole, UK). 
 
2.2.4 Complete NAbs culture medium 
Component  Volume (ml) 
DMEM 500 
FBS 57 
Glutamine 6 
7.5% w/v NaHCO3 
solution 
6 
HAT 1 vial 
  
Complete culture medium  
Culture medium (above) 100 
1 % 
Antibiotic/Antimycotic 
1 
 
Table 2.3: Preparation of NAbs culture medium. DMEM, FCS (Invitrogen, 
Paisley, UK) glutamine, NaHCO3, HAT and antibiotic-antimycotic solution (Sigma-
Aldrich, Poole, UK). 
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2.2.5 Heat-inactivated IFN (HI-IFN) 
1-10 g/ml working solution of recombinant IFN (Betaferon® or Rebif®) in RPMI-
1640 was incubated on a heating block at 75oC for 1.5 hours. 
  
2.3 Depletion reagents  
The reagents used for depleting cells in this project were anti-CD20 antibody 
(18B12, IgG2a; Biogen Idec, Cambridge, Massachusetts, USA), YTS191 CD4 
depleting monoclonal antibody (Bio X Cell, West Lebanon, New Hampshire, USA) 
and mitoxantrone (Mayne Pharma, Warwickshire, UK).  
 
(1) 2.5 mg/ml of anti-CD20 antibody was prepared by adding 1 ml anti-CD20 
antibody stock solution (5.67 mg) to 1.268 ml PBS. Animals were injected 
intravenously with 100 l anti-CD20 antibody (250 g/mouse).   
 
(2) 2 mg/ml of anti-CD4 antibody was prepared by adding 1 ml anti-CD4 antibody 
stock solution (10 mg) to 4 ml PBS. Animals were injected intraperitoneally 
with 100 l anti-CD4 antibody (200 g/mouse). 
 
(3) 625 g/ml of mitoxantrone was prepared by adding 1 ml mitoxantrone stock 
solution (2 mg) to 2.2 ml PBS. Animals were injected intraperitoneally with 
100 l mitoxantrone per 25 g of mouse (62.5 g/mouse). 
 
2.4  Induction of neutralizing antibodies. 
2.4.1 Preparation of Interferon beta. 
Interferon beta (Avonex®, Biogen-Idec; Betaferon®, Bayer Schering; or Rebif®, 
Merck-Serono) was diluted in PBS.  
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(1) 667 g/ml Avonex® was prepared by adding 1 mg Avonex to 1.5 ml PBS; this 
was further diluted 1:1 with CFA and animals injected sub-cut with 300 l 
(100 g Avonex per mouse). 
 
(2) 133 g/ml Betaferon® was prepared by adding 1 mg Betaferon to 7.5 ml 
PBS; this was further diluted 1:1 with CFA and animals injected sub-cut with 
300 l (20 g Betaferon per mouse). 
 
(3) 1.25 mg/ml Rebif® was prepared by adding 6.5 mg Rebif to 4.7 ml PBS. 
Animals were injected i.v. with 100 l (125 g Rebif per mouse). 
 
2.4.2 Preparation of Inoculum for NAbs induction. 
A stock solution was prepared (Stock A) consisting of 4 ml incomplete Freud’s 
adjuvant (Difco, Becton Dickinson, Oxford, UK), 16 mg Mycobacterium tuberculosis 
H37Ra and 2 mg Mycobacterium butyicum. This was stored at 4oC and discarded 
after a month. Mycobacterium stock was stored at -70oC. Complete Freund’s 
adjuvant was prepared by adding 1 ml stock A to 11.5 ml incomplete Freund’s 
adjuvant and vortex mixed before use. CFA is thought to enhance T cell responses 
and antibody production when used as an adjuvant in experimental models (Billiau 
& Matthys, 2001). 
 
20 ml syringes (Becton Dickinson, Oxford, UK) were used to make up the inoculum 
solution. The plunger cap of the syringe was removed and the barrel was plugged 
with a stopper cap (Scientific Laboratory Supplies, Nottingham, UK). 5 ml diluted 
IFN solution (section 2.4.1) was added to 5 ml CFA in drops while vortexing to mix. 
The 20 ml syringe containing the solution was sonicated for 10 minutes in a 
40 
 
waterbath sonicator (Bransonic Ultrasonicator, Sigma, UK), this was to thicken the 
solution. The solution was then placed on ice to cool. A 1 ml syringe (Becton 
Dickinson, Oxford, UK) was inserted into the 20 ml syringe and the solution was 
pumped using the 1 ml syringed until it had thickened sufficiently that the solution 
did not disperse when a drop was added to water. The cap on the 20 ml syringe was 
removed and replaced with a 6 cm large bore needle and the solution dispensed into 
1 ml syringes. A 16 mm 25 g needle (Becton Dickinson, Oxford, UK) was fixed to 
the 1 ml syringes and the needle cover pushed firmed onto the needles.  
 
2.4.3 Injection of animals 
Mice between 6-8 weeks were immunized. Mice were held at the nape of the neck 
and by the tail on a wire mouse cage. The skin of the dorsal surface of the flank was 
lifted and the needle inserted subcutaneously into the mouse. 150 l of IFN 
solution was injected into the right flank and another 150 l was injected into the 
left flank. Mice were injected subcutaneously with various concentrations (5, 10, 20, 
50, 70 or 100 g) of rhIFN (Avonex®, Biogen-Idec; Betaferon®, Bayer Schering; 
or Rebif®, Merck-Serono). This was Day 0 and the process was repeated depending 
on the immunization protocol, and the injections were more posterior to the original 
injections. 
 
2.5 Induction of Experimental Allergic Encephalomyelitis. 
2.5.1 Preparation of spinal cord homogenate 
Spinal cords from mice were removed and homogenised in a glass hand 
homogeniser and placed in -70oC freezer overnight. The homogenate was freeze 
dried for 24-48 hours in a freeze dryer (Edwards, Crawley, UK). The homogenate 
was ground to a fine powder and stored at -20oC. 
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2.5.2 Preparation of inoculum for spinal-cord induced disease in ABH mice 
The procedure was followed as above in 2.4.2 except that 5 ml IFN solution was 
replaced with 5 ml PBS containing 33 mg of freeze dried spinal cord homogenate 
(6.6 mg/ml). 
  
2.5.3 Injection of animals 
Mice between 6-8 weeks were immunized following the procedure in section 2.4.3 
except that mice were immunized with spinal cord homogenates on Days 0 and 7 as 
previously described (Baker et al., 1990). Acute hind-limb paralysis developed 
typically between 2-4 weeks after injection of SCH. A relapse could be induced 7-8 
days after a further injection of spinal cord homogenates (O’Neill at al 1991) and 
mice were immunized subcutaneously in the flank with SCH in Freund’s adjuvant 
supplemented with 60 g Mycobacterium tuberculosis H37Ra and Mycobacterium 
butyricum on day 28-30. 
 
2.5.4 Clinical disease scoring 
Animals developing EAE were scored and weighed daily using a 5-point EAE scale 
(figure 2.1).  
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Figure 2.1: EAE scoring scale. EAE severity was scored following a 5-point scale. 
Paralytic clinical disease was scored daily: 0=normal, 1=limp tail, 2=impaired 
righting reflex, 3=hind-limb paresis, 4=complete hind-limp paralysis and 
5=moribund/death; signs of reduced severity were scored at 0.5 less than the 
indicated grade as previously described (Baker et al., 2001). 
 
2.6 Tissue sampling 
2.6.1 Blood sampling and analysis 
Cardiac or tail bleeds were collected in Eppendorff tubes containing heparin (Sigma-
Aldrich, Poole, UK), samples were centrifuged and plasma/serum collected. Serum 
and plasma samples were taken from the mice prior to and post immunization. 
 
2.6.2 Spleen sampling and analysis 
Spleens were removed from dead mice killed by schedule 1 method and placed in 
PBS on ice or at 4oC. The spleens were forced through a 40 m cell strainer into 
RPMI-1640 (Invitrogen, Paisley, UK) to form a cell suspension. Red cells were lysed 
by addition of 1 ml lysis buffer for a minimum of 1 minute at room temperature. 
 Limp tail 
Impaired                
righting reflex 
hindlimb 
paralysis 
Moribund 
 partial 
paralysis 
 Normal 
Remission 
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The number of viable cells was determined by trypan blue (Sigma-Aldrich, Poole, 
UK) exclusion method. Splenocytes were resuspended at 1-2x106 cells/ml in PBS.  
 
2.7 Assessment of immune function 
2.7.1 Surface antibody staining 
1x106 cells/ml of splenocytes was stained with 1:10 dilution of surface antibodies 
(Table 2.4) in FACS buffer for 30 minutes in the dark. Cells were washed and fixed 
by addition of 100l Caltag Medium A fixative (Caltag, Buckingham, UK) and 
incubated for minimum 15 minutes in the dark at room temperature. The cells were 
washed and resuspended in 300 l of FACS buffer and analysed by flow cytometry 
(Becton Dickinson, Oxford, UK). 
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Target Fluorochrome Clone Manufacturer 
CD4 FITC YTS191.1 Serotec 
F4/80 FITC BM8 eBiosciences 
CD4 PE RM4-5 Caltag 
IFN PE XMG1.2 BD Pharmingen 
FoxP3 PE FJK-16s eBiosciences 
IgG2a PE - eBiosciences 
CD25 PE-Cy7 PC61 BD Pharmingen 
CD3 PE-Cy7 145-2C11 BD Pharmingen 
CD8 PerCP 53-6.7 BD Pharmingen 
CD4 APC RM4-5 BD Pharmingen 
CD45R/B220 APC RA3-6B2 BD Pharmingen 
Streptavidin APC-Cy7 Streptavidin BD Pharmingen 
CD44 Biotin IM7 BD Pharmingen 
CD28 - 37.51 BD Pharmingen 
CD49d - R1-2 BD Pharmingen 
 
Table 2.4: Fluorochrome-conjugated antibodies used for labeling cells 
analyzed by flow cytometry. Fluorochrome abbreviations: FITC-fluorescein 
isothiocyanate, PE-phycoerythrin, PE-Cy7- tandem between Phycoerythrin and 
cyanine 5, PerCP-Peridinin-chlorophyll protein, APC-allophycocyanin, APC-Cy7- 
tandem between Allophycocyanin and cyanine 7. 
 
2.7.2 Intracellular cytokine staining 
1 ml aliquots were made by resuspending splenocytes from section 2.6.2 in 
complete culture medium at approximately 1-2x106 cells/ml (1x106 cells per test). 
Anti-CD28 (1 g) and anti-CD49d (1 g) antibodies (BD Pharmingen, Oxford, UK) 
were added to each tube and incubated for 10 minutes at room temperature. Cells 
were incubated with 1 ml of diluted antigen (table 2.5) or complete media per tube 
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for 1 hour at 37oC, 5% CO2. Cells were further incubated with 10 g of Brefeldin A 
(Sigma-Aldrich, Poole, UK) per tube overnight at 37oC humidified atmosphere 
containing 5% CO2 (maximum of 18 hours incubation). 
After overnight incubation, the cells were washed in FACS buffer and resuspended. 
Fluorochrome conjugated surface antibodies (table 2.4) were added and incubated 
for 30 minutes at room temperature in the dark and cells washed in FACS buffer. 
Cells were fixed by adding 100 l of fixative reagent A (Becton Dickinson, Oxford, 
UK) and incubated for 15 minutes at room temperature in the dark. Cells were 
washed and 100 l diluted fluorochrome conjugated anti-cytokine antibodies (table 
2.4; antibodies diluted in permeabilizing buffer reagent B, Becton Dickinson, Oxford, 
UK) were added and incubated for 30 minutes at room temperature in the dark. The 
cells were washed and resuspended in 300 l of FACS buffer and analysed by flow 
cytometry (Becton Dickinson, Oxford, UK). IFN 
 
Component  Initial concentration  
(/ml) 
Final concentration  
(/ml) 
IFN 500 g 10 g 
Heat-inactivated IFN 500 g 10 g 
Con-A 10 g 1 g 
PMA 40 ng 20 ng 
Ionomycin 1 g 500 ng 
 
Table 2.5: Preparation of antigen for stimulating cells. IFN (Betaferon®, 
Bayer-Schering), Con-A, PMA and Ionomycin (Sigma-Aldrich, Poole, UK). 
 
2.7.3 CFSE labelling 
Splenocytes from section 2.6.2 were resuspended in RPMI-1640 at 2-10x106 
cells/ml. 5 M 5-(and-6)-carboxyfluorescein diacetate, succinimidyl ester (CFSE) 
(Sigma-Aldrich, Poole, UK) was added per ml of cell suspension and incubated for 
46 
 
10 minutes at 37oC. The reaction was stopped by addition of equal volume of FCS. 
The cells were then washed and resuspended at 1-4x106 cells/ml complete culture 
medium. Cells were used in sections 2.7.4 and 2.7.5. 
 
2.7.4 Proliferation assay 
Cells labelled with CFSE (section 2.7.3) were resuspended at 1-4x106 cells/ml in 
complete culture medium. 1 ml test aliquots (2x106 cells) were made and 1 ml 
diluted antigen (table 2.4) or complete culture medium was added to each aliquot 
and incubated for 3 days at 37oC humidified atmosphere containing 5%CO2. 
After incubation, the cells were washed and resuspended in FACS buffer. 
Fluorochrome conjugated surface antibodies (table 2.4) were added and incubated 
for 30 minutes at room temperature in the dark. The cells were washed and 
resuspended in FACS buffer. Cells were fixed by addition of 100 l of fixative 
reagent A and incubated for 15 minutes at room temperature in the dark. The cells 
were washed and resuspended in 300 l of FACS buffer and analysed by flow 
cytometry.  
 
2.7.5 Proliferation assay with cytokine production 
The process was followed in section 2.7.4 except that for the last 5 hours of the 
overnight incubation 20 ng Phorbol 12-myristate 3-acetate (PMA), 500 ng 
ionomycin and 5 g Brefeldin A (Sigma-Aldrich, Poole, UK) was added to each test. 
Another exception was after incubating cells with fluorochrome conjugated surface 
antibodies and fixation, cells were further incubated for 30 minutes at room 
temperature in the dark with 100 l diluted fluorochrome conjugated anti-cytokine 
antibodies (table 2.4; antibodies diluted in permeabilizing buffer reagent B). The 
cells were washed and resuspended in 300 l of FACS buffer and analysed by flow 
cytometry. 
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2.8 Neutralizing antibody assay 
2.8.1 Cell culture 
The HL-116 cell line (Dr Gilles Uze, University of Montpellier, France) was used in 
this assay. This is a human fibrosarcoma cell line which has been stably transfected 
with firefly luciferase gene which is linked to the interferon stimulated response 
element. When IFN binds to its receptor, the receptor cassette is activated and 
luciferase is released.  
Frozen HL-116 cells were thawed and cultured in complete NAbs medium in 80 cm2 
culture flasks at 37oC, with 5% CO2. Cells were sub-cultured when approximately 
85% confluent when examined using a light microscope. Culture medium was 
discarded and 4 ml trypsin/EDTA (Sigma- Aldrich, Poole, UK) was added and 
incubated until cells were detached from culture flask. 1 ml FBS was added to inhibit 
the trypsin, and detached cells were aspirated and washed in PBS. Cells were 
counted using the trypan blue exclusion method and resuspended at 4x105 cells/ml. 
100 l of HL-116 cell suspension was added to each well of a 96 well plate (Greiner 
Bio-One, Stonehouse, UK) giving a final concentration of 4x105 cells/well. Cells were 
incubated overnight at 37oC humidified atmosphere containing 5%CO2.  
 
2.8.2 Preparation of IFN standard and samples 
IFN (Betaferon) was prepared by dissolving 1 vial in 16 ml NAbs culture medium to 
give a concentration of 1x106 U/ml. This was serially diluted to give a working 
solution of 1000 U/ml (table 2.6). 
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IFN (U/ml) IFN (ml) Medium (ml) Final IFN (U/ml) 
1,000,000 1 9 100,000 
100,000 1 9 10,000 
10,000 1 9 1,000 
 
Table 2.6: Preparation of IFN stock solution. 
 
Interferon standard curve (100-3.125 U/ml) was prepared by serial dilution of stock  
solution (table 2.7). 
 
IFN (U/ml) IFN (ml) Medium (ml) Final IFN (U/ml) 
1000 1 4 200 
200 4 4 100 
100 2 2 50 
100 4 16 20* 
50 2 2 25 
25 2 2 12.5 
12.5 2 2 3.25 
6.25 2 2 3.125 
3.125 2 2 1.5625 
 
Table 2.7: Preparation of IFN Standard curve. 20* U/ml was added to each 
diluted sample. 
 
Samples were diluted in NAbs culture medium (table 2.8) 
 
 Sample conc. Sample (l) Medium (l) Dilution factor 
Neat  15 285 1:20 
1:20 100 100 1:40 
1:40 150 150 1:80 
1:80 150 150 1:160 
 
Table 2.8: Preparation of plasma and serum samples. 
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2.8.3 Incubation of samples with IFN. 
150 l diluted samples (table 2.8) were incubated with 150 l diluted IFN (table 
2.7) for 1 hour at room temperature. Final concentration of IFN was 10 U/ml. After 
incubation, 100 l/well of the sample/IFN mixture was added to the HL-116 cells; 
IFN standards were added in doubling dilutions to the cells and were incubated for 
4 hours at 37oC humidified atmosphere containing 5%CO2. The plates and the 
‘Promega Steady-Glo Luciferase Assay System’ were brought to room temperature. 
The Promega steady-Glo (Promega, Southampton, UK) was added to each well (50 
L) and incubated for 10 minutes at room temperature, and the plates were read on 
the Wallac Victor2 1420 Multilabel Counter Plate Reader set to read at 
luminescence. 
 
2.8.4 Determination of the 50 % endpoint and Kawade correction factor 
The Kawada technique defines the neutralization potency of serum as the titre that 
reduces IFN bioactivity from 10 LU/ml to 1 LU/ml (ten-fold reduction in bioactivity 
of IFN). The concentration of IFN at the 50% endpoint is defined as 1 LU/ml, this 
is the point where 50% of the biological effect of IFN is lost. A curve was 
constructed by plotting Log10 IFN dilution (x-axis) vs. Log10 LCPS (y-axis) to 
illustrate the dose-response of the cells to stimulation with IFN. From these curves 
the maximal and minimal responses (anchor points) were identified and the 50% 
endpoint calculated.  The minimal limit was set as the minimum amount of light the 
cells without any IFN stimulus emit under the established conditions of the assay 
and the upper limit was taken as the maximum amount of light emitted by cells 
maximally stimulated by a concentration of IFN that is considered to be saturating 
the transfected cell line.  
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Figure 2.2: Maximum and minimum LCPS and 50% endpoint. LCPS is 
luciferase counts per second. 
 
The concentration of IFN at the 50% endpoint is defined as 1 LU/ml. 
50% endpoint = Average (Log10 Max LCPS and Log10 Min LCPS) 
 
The concentration of IFN at the 50% endpoint was calculated from the linear 
appearing part of the curve (figure 2.2) which was expanded and a trend-line fitted 
with an equation and R2 value. This equation was used to calculate the Log IFN 
dilution at the 50% endpoint (1 LU/ml). This was in turn used to determine the IFN 
dilution (IFN dilution = 10^LogIFN dilution) and to calculate the LU/ml used to stimulate 
the cells in the assay.  
 
n =        IFN dilution at 1 LU/ml   
             IFN dilution used on cells 
  
The value (n) was used in the Kawade formula as a correction factor. The ten-fold 
reduction (TRU/ml) in biological effect of IFN was calculated using the formula:  
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t = f (n-1) 
   9 
 
t is the titre, n is the number of LU/ml of IFN applied to the samples, and f is the 
dilution of antibody at the 50% endpoint.  
The 50% endpoint was also used to calculate the percentage inhibition for each 
sample tested.  
%Inhibition = (50% endpoint - Sample LCPS) x 100 
          50% endpoint 
 
 
2.9 Statistical analysis 
2.9.1 NAbs assay 
Statistical analysis and graphs for the NAbs assays were prepared using Microsoft 
Office Excel (2007).  
 
2.9.2 EAE Clinical score  
The clinical score data is presented as the mean daily clinical score +/- standard 
error of the mean (SEM), the mean maximal clinical score of each group (group 
score) +/- SEM or the number of animals with EAE per group. Differences in clinical 
scores were assessed using non-parametric, Mann-Whitney U statistics (O'Neill et 
al., 1993; Pryce et al., 2003). Statistical analysis was performed by GraphPad Prism 
(GraphPad software, La Jolla, USA). Results were considered significantly different if 
the probability level P<0.05 (*), P<0.01(**) or P<0.001(***) was reached between 
groups. 
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2.9.3 Proliferation and cytokine assays  
Differences in cytokine production and proliferative responses were assessed by 
Students t test analysis using GraphPad Prism (GraphPad software, La Jolla, USA). 
Differences in cell proportions were assessed by Students t test analysis using 
GraphPad Prism. Results were considered significantly different if the probability 
level P<0.05 (*), P<0.01(**) or P<0.001(***) was reached between groups. 
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Chapter 3 
3 Establishment of neutralizing antibody model 
 
3.1 Introduction 
Interferon-beta (IFN) is one of the first line treatments for multiple sclerosis (MS). 
Neutralizing antibodies (NAbs) to IFN develop over treatment time and these affect 
the bioavailability of the drug. The aim of this chapter is to develop a neutralizing 
antibody model in the mouse similar to that observed in MS patients with NAbs to 
IFN. This model can be used to study the effects of tolerization strategies on the 
outcome of NAbs to IFN and indirectly on the outcome of IFN treatment in MS. 
 
We elected to study NAbs in the context of IFN rather than MS directly to 
investigate the effects of tolerization strategies on the outcome of NAbs and 
indirectly on the outcome of IFN treatment in MS disease.  In MS, autoimmunity is 
unproven, the auto-antigens are not well defined and if the tolerization strategy 
goes wrong, it could exacerbate the disease (Vergelli et al., 1996); while in NAbs 
positive patients on IFN treatment, autoimmunity is proven, the auto-antigen and 
time course for developing antibodies is known and patients that already have a 
NAbs response are not physically unwell. The loss of endogenous IFN activity as a 
result of NAbs does not cause disease but has been shown to reduce the availability 
of IFN(Malucchi et al., 2004).  
 
Biozzi ABH mice and BALB/c mice were the 2 mouse models chosen to investigate 
the development of NAbs to human IFN.  
The ABH Biozzi mouse is used in experimental autoimmune encephalomyelitis (EAE) 
which is an autoimmune mouse model of MS; EAE can be induced by several CNS 
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peptides and by spinal cord homogenates in this model (Baker et al., 1990). Biozzi 
ABH mice tend to produce a T helper1 (Th1) type immune response to foreign 
antigen and they produce mainly IgG1 antibodies (Baker et al., 1990). This model 
was chosen as it is extensively used in our lab and by others as a model for MS. 
 
BALB/c model is not routinely used as an EAE model, though it has been used to 
study the involvement of B cells in development of EAE (Lyons et al., 2008). The 
BALB/c model is a T helper2 (Th2) biased model; Th2 T cells drive humoral 
immunity and allergic responses and produce IL-4 in an immune response. BALB/c 
has been used as a model to study a number of Th2-biased diseases including 
asthma. This model has been chosen as they produce antibodies readily in response 
to foreign antigen. 
 
3.1.1 Development of antibodies to human Interferon beta 
Interferons stimulate cellular responses to regulate viral infections, modulate the 
immune system and cell survival. Type 1 interferons have anti-viral activity and 
were developed for MS treatment as a result of this action (Borden et al., 2007). 
The action of IFN in MS is unknown. It is thought that IFN acts on immune cells 
by modulating their actions via cytokine production skewing their response from an 
interferon-gamma (IFN) producing Th1 response towards a Th2 response (Hartung 
et al., 2004). IFN has the ability to reduce proliferation of lymphocytes by 
decreasing expression of activation markers such as IL2 receptors and IL10 an 
immunosuppressive cytokine, and thereby reduces the migration of activated 
inflammatory cells through the blood brain barrier (BBB) into the central nervous 
system (Noronha et al., 1993; Rudick et al., 1998). IFN has been shown to reduce 
relapse rates in relapsing-remitting MS and prolong the time to confirmed 
progression in secondary progressive MS (Group, 2001). 
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Interferon is transiently produced in response to viruses and bacteria (Akira et al., 
2006). IFN modulates immune cells by binding to IFN/ receptors found on these 
cells (Zhang et al., 2008). There are two forms of licensed IFNfor the treatment of 
MS: IFN-1a and IFN-1b. IFN-1a (Avonex® and Rebif®) is produced in Chinese 
hamster ovary cells and its amino acid sequence is identical to that of the natural 
IFN(Kagawa et al., 1988b). IFN-1b (Betaferon®) on the other hand is produced 
in Escherichia coli and its sequence is slightly different to the natural sequence; the 
cystine residue is substituted with serine at position 17 and it lacks methionine-1 
and is non-glycosylated (McCullagh et al., 1983). Antibodies to IFN develop over 
treatment time (Hartung et al., 2007); this could be due to the difference in 
structure of IFN-1a and IFN-1b from the natural protein (Kagawa et al., 1988b; 
McCullagh et al., 1983), IFN formulation, chronic administration of large amounts 
of protein and route of delivery. 
 
Some IFN-specific antibodies termed binding antibodies (BAbs) bind IFN but do 
not significantly affect the binding of IFN to its receptor or the activity of the 
protein. BAbs may form immune complexes with IFN which are cleared from the 
circulation (Perini et al., 2001). Another group of IFN-specific antibodies termed 
neutralizing antibodies (NAbs) can abrogate or neutralize the biological activity of 
IFN by blocking the binding of IFN to its receptor mainly found on immune cells 
(Malucchi et al., 2004).  
 
Varying frequencies of BAbs (10 to 90%) and NAbs (2 to 47%) have been reported 
in MS patients (Bertolotto et al., 2004; Giovannoni et al., 2004). Up to 35% of MS 
patients develop NAbs to IFN within 2 years of starting treatment; of these 
patients, approximately 30% will revert to a NAbs negative status. Persistently high 
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positive titres of NAbs have been associated with a greater number of relapses or 
more progression in MS patients (Francis et al., 2005). There is a faster 
development of NAbs in IFN-1b-treated patients in comparison with IFN-1a-
treated patients; a higher protein dose of IFN-1b is used by patients and may be 
responsible for this (Ross et al., 2000).  
 
3.1.2 Establishment of neutralizing antibodies to human interferon beta in 
mouse models 
Interferon is produced in mice and in humans and there are differences in structure. 
Interferons mediate their effects by binding to the receptor on cells of the immune 
system; it has been shown previously that human cells are non-responsive to 
murine IFN (Qin et al., 2001). Administration of recombinant human IFN(rhIFN) 
will be seen by the mouse immune system as a foreign protein and an immune 
response should be mounted. The route of antigen introduction and the dose (high 
or low dose) is critical in determining the outcome of an immune response. 
Intravenous and mucosal administration of antigen for example, favours the 
induction of tolerance to the antigen. On the other hand subcutaneous and 
intraperitoneal administration of antigen favours an immune response mainly by 
antibody production.  
 
   
P01575 IFNB_MOUSE 1  
  
MNNRWILHAAFLLCFSTTALSINYKQLQLQERTNIRKCQELLEQLNGKINLTYR--ADFK 58 
P01574 IFNB_HUMAN 1  
  
MTNKCLLQIALLLCFSTTALSMSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFD 60 
 * .  *:  :*:  *:********** :. *:  *  :  : * :.      :**:**  **** :::       :          
:*. 
 
Table 3.1: Interferon beta amino acid sequence alignment between mouse 
and human. * signifies similar amino acid and : & . signifies different amino acids. 
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A transgenic mouse model resistant to human IFN has been developed and used to 
study the breaking of tolerance to rhIFN (van Beers et al., 2011). The model has 
the human IFN gene and sees the protein as “self” protein and will not normally 
mount a response to the protein. In transgenic mouse study, rhIFN were oxidized 
and aggregated before immunizing these transgenic mice and these forms of IFN 
broke tolerance and NAbs were observed in these mice. In the transgenic model, 
NAbs to rhIFN were as a result of breaking of tolerance. In the BALB/c model used 
by group of Bellomi, administration of rhIFN resulted in NAbs to the protein as the 
protein was seen as a foreign (Bellomi et al., 2007). The transgenic mouse model is 
less suitable to predict immunogenicity of IFN or to study tolerization strategies 
regarding NAbs formation as the mechanism of NAbs formation in this model is by 
the breaking of tolerance. The BALB/c NAbs model offers a more suitable model for 
use in investigating induction of tolerance to rhIFN following the induction and 
formation of NAbs. The main mechanism of NAbs formation in the BALB/c model is 
similar to that observed in IFN-treated MS patients with NAbs which is as a result 
of an immune response to the protein. 
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3.2 Results 
3.2.1 Induction of neutralizing antibodies in ABH mice 
Mice were immunized with recombinant human IFN (Avonex®, Betaferon® or 
Rebif®) in CFA via the sub-cutaneous route (section 2.4); and sera/plasma samples 
collected (section 2.6) and tested in the neutralizing antibody assay (section 2.8). 
The 50% point between maximum and minimum log LCPS (luminescent counts per 
second) was determined and used to calculate the percentage inhibition; titres were 
also calculated for each sample tested (section 2.8.4). Naïve, unimmunized mice 
serum was used as a negative control.  
 
Biozzi ABH mice (n=3) were immunized subcutaneously on days 0 and 7 with 100 
g of rhIFN1a (Rebif®, Serono) in CFA per immunization (figure 3.1). 
 
 
Figure 3.1: Timeline for immunization schedule for the administration of 
interferon-beta in mice. Biozzi ABH mice (n=3) were immunized with 100 g 
Rebif® in complete Freund’s adjuvant on days 0, 7, 89 and 96. Plasma/Serum 
samples were taken and tested in the NAbs assay on Days 29, 83 and 110. 
 
Serum samples were collected on day 29 and tested in the neutralizing antibodies 
(NAbs) assay. NAbs were observed in these mice as shown in figure 3.2. 
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Figure 3.2: Neutralizing antibodies to Interferon-beta in ABH Biozzi mice. 
ABH mice (n=3) were immunized with 100 g of rhIFN1a (Rebif®) in complete 
Freund’s adjuvant on days 0 and 7; plasma samples were tested in the NAbs assay 
on day 29. Naïve mouse serum was used as a control and was not immunized. 
%inhibition is the percentage of IFN that was inhibited by the sample upon 
incubation with IFN. Titres less than 20 were deemed NAbs negative and titres 
between 20 and >320 were deemed positive. NAbs to IFN were observed in all 3 
test mice.   
 
These mice were tested for NAbs on day 83 to investigate whether or not the NAbs 
observed post immunization were still detectable (figure 3.3a). No NAbs were 
observed in the test mice; the mice were further immunized with rhIFN (Rebif®) in 
CFA a third and fourth time (day 89 and 96) to see if NAbs could be re-induced in 
these mice. NAbs to IFN was observed in 1 of the test mice following these 
immunizations (figure 3.3b).  
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Figure 3.3: Neutralizing antibodies to Interferon-beta in ABH Biozzi mice. 
ABH mice (n=3) were immunized with 100 g of rhIFN1a (Rebif®) in complete Freund’s 
adjuvant on days 0, 7 (a), or days 0, 7, 89 and 96 (b); plasma samples were tested in the 
NAbs assay on days 83 (a) or 110 (b). Naïve mouse serum was used as a control and was not 
immunized. %inhibition is the percentage of IFN that was inhibited by the sample upon 
incubation with IFN. Titres less than 20 were deemed NAbs negative and titres between 20 
and >320 were deemed positive. No NAbs to IFN was observed in all 3 test mice on day 83 
(a) and only in 1 of the test mice on day 110 (b) had NAbs to rhIFN.   
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The terminal mice splenocytes were sampled in an intracellular cytokine assay (ICS) 
to investigate the cytokine response to recall antigen (rhIFN). No significant 
increase in antigen-specific responses over the control responses was observed in 
both CD4 and CD8 T cells (figure 3.4). 
 
Proliferative responses to human IFN were investigated in the splenocytes at the 
terminal time point. Splenocytes were incubated for 3 days with CFSE (to 
investigate proliferative responses) and then cells were stained for CD4 and CD8 T 
cells. The control samples were not stimulated with IFN (No Antigen). The 
percentage of proliferating CD4 or CD8 T cells producing IFN in response to human 
IFN was calculated. A significant antigen-specific response to IFNwas observed in 
CD4 T cells in 1 mouse (Figure 3.5) and in 2 mice for CD8 T cell responses (Figure 
3.6). The results observed here shows that though the samples at this time point 
may not have had detectable NAbs, they had cytokine responses in response to 
presentation of human IFN. 
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A) 
 
B) 
 
C) 
 
Figure 3.4: T cell responses to human Interferon-beta in ABH Biozzi mice. 
ABH mice (n=3) were immunized with 100 g of rhIFN1a (Rebif®) in complete Freund’s 
adjuvant on days 0, 7, 89 and 96; splenocytes were tested in the intracellular cytokine assay 
on day 110. No significant antigen-specific IFN responses by CD4 or CD8 T cell was observed 
in test mice over control responses (no antigen controls). Graphs A), B) and C) represents 
each mouse tested. HI IFNb is rhIFN heated at 75oC for 1.5 hours. 
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Figure 3.5: Proliferative CD4 T cell responses to human Interferon-beta in 
ABH Biozzi mice. ABH mice (n=3) were immunized with 100 g of rhIFN1a 
(Rebif®) in complete Freund’s adjuvant on days 0, 7, 89 and 96; splenocytes were 
tested in the proliferation assay on day 110. Antigen-specific IFN response by CD4 
T cells was observed in 1 test mice over control responses (no antigen controls).  
 
Figure 3.6: Proliferative CD8 T cell responses to human Interferon-beta in 
ABH Biozzi mice. ABH mice (n=3) were immunized with 100 g of rhIFN1a 
(Rebif®) in complete Freund’s adjuvant on days 0, 7, 89 and 96; splenocytes were 
tested in the proliferation assay on day 110. A significant antigen-specific IFN 
response by CD8 T cells was observed in 2 test mice over control responses (no 
antigen controls).  
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Following this study and following discussions with a Statistician, the number of 
mice was increased in each group. ABH mice (n=30) were immunized 
subcutaneously on days 0, 7 and 21 with 5, 10 or 20 g of human IFN in CFA per 
immunization (figure 3.7). The immunization schedule was changed to mimic the 
one routinely used in the lab for inducing EAE in the EAE mouse model. 
 
 
Figure 3.7: Timeline for immunization schedule for the administration of 
interferon-beta in mice. Biozzi ABH mice were immunized with 5, 10 or 20 g 
Rebif® (n=15) or 5, 10 or 20 g Betaferon® (n=15) in complete Freund’s adjuvant 
on days 0, 7 and 21. Plasma/Serum samples were taken on Days 19 and 38. 
 
Half (n=15) of the mice were given Rebif® new formulation (IFN-1a) and the other 
half (n=15) were given Betaferon® (IFN-1b). Plasma samples were taken on days 
19 (pre-third immunization) and day 38 (2 weeks post third immunization) and 
tested in the NAbs assay. None of the samples were NAbs positive on day 19 (data 
not shown). On day 38, 33% of test mice (n=5) were NAbs positive following high 
dose Betaferon; on the other hand with Rebif, 80-100% of test mice were NAbs 
positive across all the doses given (figure 3.8 and table 3.1). 
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Figure 3.8: Neutralizing antibodies to Interferon-beta in ABH Biozzi mice.  
Biozzi ABH mice were immunized with 5, 10 or 20 g Rebif® (n=15) or 5, 10 or 20 
g Betaferon® (n=15) in complete Freund’s adjuvant on days 0, 7 and 21; plasma 
samples were tested in the NAbs assay on day 38. Naïve mouse serum (mouse 4) 
was used as a control and was not immunized. %inhibition is the percentage of IFN 
that was inhibited by the sample upon incubation. Titres less than 20 were deemed 
NAbs negative and titres between 20 and >320 were deemed positive. NAbs to IFN 
was observed in 18 of the 30 test mice. 
 
 5 g 5 g 10 g 10 g 20 g 20 g 
Product Negative Positive Negative Positive Negative Positive 
Betaferon 5  
(<20) 
- 5  
(<20) 
- 2  
(<20) 
3  
(159) 
 
Rebif 1  
(<20) 
4  
(>320) 
- 5  
(>320) 
1  
(<20) 
4  
(>320) 
 
Table 3.2: Neutralizing antibodies to Interferon-beta in ABH Biozzi mice 
following immunization with Betaferon or Rebif. 
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Due to lack of consistent NAbs induction in these mice with Betaferon, the amount 
of human IFN was increased to see if that could induce detectable NAbs in this 
model. Each group of mice (n=5) were given 20, 50, 70 or 100 g Betaferon® in 
CFA per immunization on days 0, 7 and 21. Plasma samples were taken on day 35 
and tested in the NAbs assay. Similar results were observed as was seen in figure 
3.8 and table 3.1, even with an increase in the amount of rhIFN given at 
immunization. The terminal splenocytes from mice immunized with Betaferon were 
sampled in an intracellular cytokine assay (ICS) to investigate the cytokine 
response in the memory cells to recall antigen (rhIFN) detailed in section 2.7. An 
IFN-specific response by memory CD4 and CD8 T cells were observed in all the 
mice immunized with 100 g Betaferon (figure 3.9) and 20 g Betaferon (figure 
3.12). 4 out of 5 mice immunized with 70 g Betaferon (figure 3.10) and 50 g 
Betaferon (figure 3.11) had IFN-specific IFN responses by memory CD4 and CD8 T 
cells. These results show that a memory cytokine response had developed over 
time, even though the levels of NAbs were not detectable in these studies.   
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A)  
 
B)  
 
Figure 3.9: Memory T cell responses to human Interferon-beta in ABH 
Biozzi mice. Biozzi ABH mice were immunized with 100 g Betaferon® (n=5) in 
complete Freund’s adjuvant on days 0, 7 and 21; splenocytes were tested in the 
intracellular cytokine assay on day 38. An IFN-specific IFN response by memory 
CD4 (A) and CD8 (b) T cells was observed in all test mice over control responses 
(no antigen controls). 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
A1 A2 A3 A4 A5
%
C
D
4
+
 I
F
N
+
 T
 c
e
ll
s
 
Animal I.D.
No Antigen
IFNb HI
IFNb
0.0
0.5
1.0
1.5
2.0
2.5
3.0
A1 A2 A3 A4 A5
%
C
D
8
+
 I
F
N
+
 T
 c
e
ll
s
 
Animal I.D.
No Antigen
IFNb HI
IFNb
68 
 
A)  
 
B) 
 
Figure 3.10: Memory T cell responses to human Interferon-beta in ABH 
Biozzi mice. Biozzi ABH mice were immunized with 70 g Betaferon® (n=5) in 
complete Freund’s adjuvant on days 0, 7 and 21; splenocytes were tested in the 
intracellular cytokine assay on day 38. An IFN-specific IFN response by memory 
CD4 (A) and CD8 (B) T cells was observed 4 of the 5 test mice over control 
responses (no antigen controls). 
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A)  
 
B) 
 
Figure 3.11: Memory T cell responses to human Interferon-beta in ABH 
Biozzi mice. Biozzi ABH mice were immunized with 50 g Betaferon® (n=5) in 
complete Freund’s adjuvant on days 0, 7 and 21; splenocytes were tested in the 
intracellular cytokine assay on day 38. An IFN-specific IFN response by memory 
CD4 (A) and CD8 (B) T cells was observed in 4 of the 5 test mice over control 
responses (no antigen controls). 
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A)  
 
B) 
 
Figure 3.12: Memory T cell responses to human Interferon-beta in ABH 
Biozzi mice. Biozzi ABH mice were immunized with 20 g Betaferon® (n=5) in 
complete Freund’s adjuvant on days 0, 7 and 21; splenocytes were tested in the 
intracellular cytokine assay on day 38. A significant IFN-specific IFN response by 
memory CD4 (A) and CD8 (B) T cells was observed in all test mice over control 
responses (no antigen controls). 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
D1 D2 D3 D4 D5
%
C
D
4
+
I
F
N
+
 c
e
ll
s
 
Animal I.D.
No Antigen
IFNb HI
IFNb
0.0
0.5
1.0
1.5
2.0
2.5
3.0
D1 D2 D3 D4 D5
%
C
D
8
+
I
F
N
+
 c
e
ll
s
 
Animal I.D.
No Antigen
IFNb HI
IFNb
71 
 
3.2.2 Induction of NAbs in BALB/c mice 
Mice were immunized with recombinant human IFN (Avonex®, Betaferon® or 
Rebif®) in CFA via the sub-cutaneous route (section 2.4); and sera/plasma samples 
collected (section 2.6) and tested in the neutralizing antibody assay (section 2.8). 
The 50% point between maximum and minimum log LCPS (luminescent counts per 
second) was determined and used to calculate the percentage inhibition; titres were 
also calculated for each sample tested (section 2.8.4). Naïve, unimmunized mice 
serum was used as a negative control.  
 
BALB/c mice (n=15) were immunized subcutaneously on days 0, 7 and 21 with 5, 
10 or 20 g of human IFN1b (Betaferon®) in CFA per immunization. This 
immunization schedule was chosen as it is used routinely in our lab for induction of 
EAE in the mouse model. Serum samples were collected on day 2, 14 and 35 (figure 
3.13).   
 
 
Figure 3.13: Timeline for immunization schedule for the administration of 
interferon-beta in mice. BALB/c mice were immunized with 5, 10 or 20 g 
Betaferon® (n=15) in complete Freund’s adjuvant on days 0, 7 and 21. 
Plasma/serum samples were taken on Days 2, 14 and 35. 
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The serum samples were tested in the NAbs assay, no NAbs were observed on days 
2 and 14 above the negative control (data not shown). NAbs were observed in 2 
mice immunized with 20 g Betaferon® on Day 35 (table 3.2). 
 
 5 g 10 g 20 g 
 %Inhibition Titre %Inhibition Titre %Inhibition Titre 
1 0 <20 52.9 22.5 92.7 55.1 
       
2 15.2 <20 26.9 <20 0 <20 
3 0 <20 12.9 <20 80.9 43.9 
4 0 <20 15.6 <20 7.9 <20 
5 0 <20 34.1 <20 44.1 <20 
 
Table 3.3: Neutralizing antibodies to Interferon-beta in BALB/c mice. 
BALB/c mice (n=15) were immunized with 5, 10 or 20 g Betaferon® in complete 
Freund’s adjuvant on days 0, 7 and 21; plasma samples were tested in the NAbs 
assay on day 35. %inhibition is the percentage of IFN that was inhibited by the 
sample upon incubation. Titres less than 20 were deemed NAbs negative and titres 
between 20 and >320 were deemed positive.  NAbs to IFN was observed in 2 of 
the higher dosed test mice.  
 
Terminal splenocytes were tested in the intracellular cytokine assay. No significant 
IFN-specific CD4 T cells responses were observed (data not shown). Figure 3.14 
shows the CD8 T cell responses observed. An IFN-specific IFN response by CD8 T 
cells was observed in all test mice but not significantly higher than the controls (no 
antigen). 
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Figure 3.14: CD8 T cell responses to human Interferon-beta in BALB/c 
mice. BALB/c mice (n=15) were immunized with 5 (A), 10 (B) or 20 (C) g 
Betaferon® in complete Freund’s adjuvant on days 0, 7 and 21; splenocytes were 
tested in the intracellular cytokine assay on day 35. No antigen was used as a 
control. An IFN-specific IFN response by CD8 T cells was observed in all test mice 
over control responses (no antigen controls). 
 
Following the results observed in table 3.2, mice were immunized with the higher 
dose of Betaferon® to see if NAbs could be established in this model. BALB/c mice 
(n=15) were immunized with 20 g Betaferon® and samples taken on day 35 (2 
weeks post the 3rd immunization) and tested in the NAbs assay. 13 of the 15 mice 
immunized were NAbs positive (table 3.3). 
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 20 g 20 g 20 g 
 %Inhibition Titre %Inhibition Titre %Inhibition Titre 
1 95.8 >320 88.1 >320 76.7 131.97 
2 94.1 >320 94.1 >320 0.6 <20 
3 91.8 >320 94.7 >320 79.9 103.1 
4 90.2 >320 86.1 >320 48.6 <20 
5 95.6 >320 95.4 >320 50.1 23.0 
 
Table 3.4: Neutralizing antibodies to Interferon-beta in BALB/c mice. 
BALB/c mice (n=15) were immunized with 20 g Betaferon® in complete Freund’s 
adjuvant on days 0, 7 and 21; plasma samples were tested in the NAbs assay on 
day 35. %inhibition is the percentage of IFN that was inhibited by the sample upon 
incubation. Titres less than 20 were deemed NAbs negative and titres between 20 
and >320 were deemed positive.  NAbs to IFN was observed in 13 of 15 test 
samples. 
 
Table 3.3 is a representative result of several experiments testing for NAbs in the 
BALB/c mice. Similar results were consistently observed in the BALB/c mice 
following immunization with 20 g Betaferon® on days 0, 7, and 21. As a result 
BALB/c mice were immunized using this protocol in subsequent experiments.  
 
To investigate the involvement of CFA in induction of NAbs to rhIFN, BALB/c mice 
(n=8) were immunized on days 0, 7 and 21 with CFA only. Serum samples were 
taken on day 35 and tested in the NAbs assay. No NAbs were observed in these 
mice (figure 3.15). 
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Figure 3.15: Neutralizing antibodies to Interferon-beta in CFA immunized 
BALB/c mice. BALB/c mice (n=8) were immunized sub-cut with complete Freund’s 
adjuvant on days 0, 7 and 21; plasma samples were tested in the NAbs assay on 
day 35. %inhibition is the percentage of IFN that was inhibited by the sample upon 
incubation. Titres less than 20 were deemed NAbs negative and titres between 20 
and >320 were deemed positive. No NAbs to IFN were observed in all mice tested.   
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3.3 Discussion 
This chapter details the establishment of a mouse NAbs model in the context of 
rhIFN, and its potential use in investigating strategies for inducing tolerance to 
rhIFN in this model (discussed in chapter 5) and indirectly in IFN-treated MS 
patients with NAbs. The Biozzi ABH mouse and BALB/c mice were both investigated 
for the establishment of the NAbs model. The BALB/c was used as it more 
consistently had NAbs to IFN in comparison to the ABH mice.  
 
It was expected that administration of rhIFN in the mouse would result in an 
immune response as the rhIFN is analogous to human IFN and not mouse IFN. 
IFN is anti-proliferative to certain cells but did not show cross-species anti-
proliferative effect in a xenograft mouse model (Qin et al., 2001). IFN is readily 
cleared from circulation and the mode of administration affects the clearance of 
IFN: subcutaneous and intramuscular administration will enhance an immune 
response to IFN in comparison with oral, mucosal or intravenous routes which 
should induce tolerance to the protein on administration. The Biozzi ABH mice and 
the BALB/c mice were the 2 mouse models chosen as they produce high levels of 
antibodies in an immune response. Therefore by investigating these 2 mouse 
models as potential NAbs models, it was hoped that results obtained in the 
development of NAbs in these mouse strains may be predictive of the responses to 
IFN observed in MS patients. The Biozzi ABH mice are used extensively in our lab 
as an EAE model, and this was the main reason it was chosen as a model for the 
establishment of NAbs to rhIFN. The ABH mice produce high levels of antibody in 
response to an antigen. The ABH mice were initially immunized with Rebif®, and 
NAbs to rhIFN were observed in these mice. Results observed also showed that the 
NAbs were not long lasting and it had previously been shown that the half-life of 
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IFN is short (Salmon et al., 1996). Further immunization with Rebif® did not 
induce NAbs in all the ABH mice immunized. Betaferon® was chosen next as it is 
generally more immunogenic in humans than the Rebif® or Avonex® (Kagawa et 
al., 1988). The different concentrations of Betaferon® (high and low) did not appear 
to consistently induce a detectable level of NAbs in the Biozzi ABH mice. NAbs to 
rhIFN has previously been observed in BALB/c mice (Bellomi et al., 2007). In the 
study, the mice were immunized with Avonex® or Rebif® (old and new 
formulations) and NAbs was observed on Day 35. They concluded that there were 
differences in the immunogenicity of different formulations of IFN available: the 
Rebif® new formulation was less immunogenic than the current formulation of 
Rebif® and Avonex® in the BALB/c mouse model. Betaferon® has been shown to 
induce NAbs more readily in humans than the other formulations of IFN and was 
the chosen formulation to be used in the development of NAbs in the BALB/c mouse 
model. The mice were initially immunized with low concentrations of Betaferon® 
and NAbs were detected in some of the mice, some of the time. On immunizing with 
20 g/ml Betaferon®, NAbs were consistently observed in more than 70% of mice 
by day 35.  
 
A human IFN transgenic mouse model has been developed (Hermeling et al., 
2005). The model expressed the human IFN gene and immune responses to 
human IFN were limited in these mice. The human IFN transgenic immune-
tolerant C57Bl/6 mice were used to study the effect of oxidation on the structure of 
rhIFN and its immunogenicity (van Beers et al., 2011). The authors showed that 
oxidation and aggregation of human IFN resulted in NAbs formation by the 
breaking of tolerance. The main difference between this transgenic model and the 
NAbs model in this chapter is that these transgenic mice are resistant to rhIFN and 
would mount a response by breaking of tolerance. In the NAbs model on the other 
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hand, an immune response is mounted as a result of the rhIFN being seen as a 
foreign protein. In MS patients with NAbs, IFN is seen as foreign and an immune 
response is mounted to the protein (Hermeling et al., 2005). The study of NAbs in 
the context of IFN was chosen rather than MS directly to investigate the effects of 
tolerization strategies on the outcome of NAbs and indirectly on the outcome of 
IFNtreatment in MS patients with NAbs to the protein.  In MS, autoimmunity is 
unproven, the auto-antigens are not well defined and if the tolerization strategy 
goes wrong, it could exacerbate the disease (Vergelli et al., 1996); while in NAbs 
positive patients on IFN treatment, autoimmunity is proven, the auto-antigen and 
time course for developing antibodies is known and patients that already have a 
NAbs response are not physically unwell. The loss of endogenous IFN activity as a 
result of NAbs does not cause disease but has been shown to reduce the availability 
of IFN and hence its bioactivity (Francis et al., 2005). The NAbs model was used to 
study tolerization strategies (discussed in chapter 5) which was hoped could be 
extrapolated for use in IFN-treated MS patients with NAbs to improve and 
hopefully prolong MS treatment with IFN. 
 
Initial exposure to a foreign protein, in this study human IFN leads to T cells being 
primed followed by a rapid expansion of these effector cells. A proportion of these 
effector cells differentiate into a memory population that are antigen experienced 
and can be long lasting. These memory cells respond rapidly to a secondary 
exposure to the same antigen. In this study, memory CD4 and CD8 T cells 
responded to IFN as was observed by their proliferative responses and IFN 
production. Prime-boost protocols in mice have been shown to increase the memory 
T cell pool, especially the CD4 T cells and this has been shown to transiently 
accelerate the development of NAbs. Though there was a T cell response to IFN in 
the ABH mice, detectable NAbs were not observed in these immunized mice. 
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In the ABH model, NAbs were observed in initial studies but we failed to observe 
detectable NAbs consistently in this model. On the other hand more consistent NAbs 
positivity was observed in the BALB/c mouse model. NAbs were consistently 
observed (70-100% positive) on Day 35 in mice immunized with 20 g/ml 
Betaferon® on days 0, 7 and 21.  
In conclusion the BALB/c mouse model was used in the development of the NAbs 
model. This model will help investigate the induction of tolerance to IFN and the 
reduction/elimination of NAbs in the model, it is hoped that the strategy will be 
useful in MS patients that have developed NAbs following IFN treatment.  
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Chapter 4 
4 Development of depletion strategy 
 
4.1 Introduction  
There are several methods that can be used for depleting cells of the immune 
system. In this project, mitoxantrone was used to deplete different immune cell 
subsets; furthermore, I used anti-CD4 depleting antibody and anti-CD20 depleting 
antibody, which deplete CD4 T cells and B cells respectively.  
The depletion of the immune cells by mitoxantrone, anti-CD4 antibody and anti-
CD20 antibody triggers a reconstitution program that leads to renewal of the T cell 
and B cell repertoire. Within this window of reconstitution, it is hoped that the 
immune system can be manipulated or “re-educated” towards a tolerogenic 
response to a particular antigen. In this chapter the antigen of interest is human 
interferon beta. 
 
4.1.1 Anti-CD4 antibody 
CD4 is a marker found on a subset of T cells in the immune system. CD4 T cells are 
involved in cellular and humoral immunity through cytokine secretion and also via 
cell-cell interaction. EAE and MS are thought to be T cell mediated diseases and CD4 
T cells have been extensively studied in these diseases (Zamvil et al., 1990). CD4 
depletion has been used to investigate the involvement of CD4 T cells in the 
development, pathogenesis and progression of EAE. Administration of YTS177 (a 
non-depleting CD4 monoclonal antibody) results in the down regulation of CD4 
which is required for T cell activation; and administration of YTS191.1 (CD4-specific 
mAb) led to a rapid reduction of CD4 T cells in the peripheral blood and lymphoid 
tissue (Cobbold et al., 1984). CD4-specific monoclonal antibody (mAb) suppresses T 
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cell dependent responses and has been shown to prevent the development of EAE 
(Cobbold et al., 1984). Selective elimination of CD4 T cells have been trialed in MS 
patients using a chimeric mAb cM-T412 (Rep et al., 1997), but the animal results 
could not be directly translated to MS.  Treatment resulted in depletion of CD4 T 
cells and these were long-lasting in these patients, however beneficial clinical 
effects measured by the number of active lesions by MRI were lacking (van Oosten 
et al., 1997). In this project, CD4 T cells were depleted in blood and in spleen using 
anti-CD4 depleting antibody.  
 
4.1.2 Anti-CD20 antibody 
B cells are an active part of the immune system. B cells develop in the bone marrow 
and then migrate to periphery and to secondary lymphoid organs (Browning, 2006). 
On encountering antigen, B cells proliferate and differentiate into antibody secreting 
plasma cells which can produce antibodies for weeks or months. Memory B cells are 
formed with the progression of an immune response and these provide a rapid 
antibody response upon a second encounter with the same antigen (Blink et al., 
2005). 
MS is considered to be primarily a T cell mediated disease, emerging evidence have 
indicated that B cells may play an important role in pathogenesis of disease both as 
antibody-secreting plasma cells and as antigen-presenting cells (APC) for the 
activation of T cells (Weber et al., 2010). Furthermore, clonally expanded B cells, 
plasma cells and antibodies to a number of MS antigens have been found in the 
central nervous system (CNS). Oligoclonal bands (OCBs) are an important 
diagnostic marker for MS. OCB are immunoglobulins and their presence in the 
cerebrospinal fluid (CSF) indicates inflammation. However, the nature of OCBs 
remains a mystery and their antigenic targets have yet to be established (Correale 
et al., 2002). 
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CD20 is a surface marker expressed by B cells from the pre-B cell phase to the 
mature B cell phase and the marker is lost during differentiation into plasma cells 
(Tedder et al., 1994). Rituximab® depletes a subpopulation of B cells (pre-B and 
mature B cells) without affecting antibody production and secretion (Petereit et al., 
2008). Rituximab is a humanized mouse monoclonal antibody against the human 
CD20 surface molecule expressed by B cells. Rituximab® has been shown to reduce 
relapse rate by about 50% in relapsing-remitting MS (Bar-Or et al., 2008) and is an 
exciting new treatment for MS. Interestingly, the positive effect was already seen 
after 12 weeks, which may highlight that Rituximab may act via direct B cell lysis or 
inflammatory mechanisms rather than by reducing the level of pathogenic 
autoantibodies. In mice, it has been shown that Rituximab depletes B cells in the 
peripheral blood, secondary lymphoid organs and in the CNS. EAE severity was 
reduced in a transgenic EAE model treated with Rituximab prior to immunization or 
at the onset of the clinical signs (Monson et al., 2011).  
Mature and memory B cells were successfully depleted using anti-CD20 antibody 
and this abrogated adaptive humoral immunity in a mouse model (DiLillo et al., 
2008). To investigate antibody responses to IFN in mice, B cells were depleted 
using anti-CD20 antibody. 
 
4.1.3 Mitoxantrone 
Mitoxantrone is an anthracenedione which acts by intercalating into the DNA 
molecule, it also interferes with RNA, and uncoiling and repair of damaged DNA by 
inhibiting topoisomerase II enzyme (Fox, 2006). Mitoxantrone acts in a dose-
dependent manner and is a potent immunosuppressive agent which inhibits in vivo 
induced proliferative response (Baker et al., 1992).  
Mitoxantrone leads to broad immunosuppression and causes a reduction in CD4 and 
CD8 T cells, macrophages and B cells in the spleen (Piao et al., 2007), and has been 
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shown to significantly reduce the severity of acute phase EAE and also can prevent 
the onset of EAE if used pre-induction in a dose-dependent manner (Baker et al., 
1992). Clinical trials data also suggest efficacy of mitoxantrone in reducing relapses 
and slowing disease progression in relapsing-remitting and secondary progressive 
MS (Debouverie et al., 2007). A nonspecific cytotoxicity effect on lymphocytes is 
believed to be a major mechanism responsible for the clinical effects of 
mitoxantrone in MS patients (Neuhaus et al., 2005). 
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4.2 Results 
4.2.1 Anti-CD4 depletion in BALB/c 
Depletion of CD4 T cells was investigated in the blood and spleen at various time 
points following a single i.p. administration of 200 g/mouse anti-CD4 antibody in 
naïve BALB/c mice (section 2.3). The time points were days 3, 7, 16 and 21 post 
i.p. administration. The volume for administration and the time points were chosen 
from results obtained by Pryce et al (Pryce et a.,l 2005). Blood and splenocytes 
were stained for T cell markers (CD4 and CD8), B cell markers (B220) and 
macrophage markers (F4/80) as detailed in section 2.7. CD4 T cells were gated 
(figure 4.1) in naïve samples as well as the time points investigated. Figure 4.1 
shows representative plots observed.  CD4 and CD8 T cells, B cells and macrophage 
cell percentages in blood (figure 4.2) and in spleen (figure 4.3) were calculated and 
naïve unimmunized mice were used as controls. A significant reduction in CD4 T cell 
proportions were observed in blood and in the spleen on all the days sampled. The 
proportion of CD4 T cells appeared to be rising on day 21 but had not reached the 
level observed in the naïve mice. A reduction in B cells in the blood and a significant 
reduction in macrophages in the spleen were also observed. 
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Figure 4.1: CD4 T cell phenotyping in BALB/c mice following administration 
of anti-CD4 antibody. Flow cytometry analysis of CD4 T cell population in naïve 
BALB/c mice post administration of anti-CD4 antibody. Splenocytes were stained for 
CD4 T cell markers; CD4 T cells were gated in the lymphoid population to determine 
proportions in naïve (a), on day 3 (b) and on day 21 (c) post administration of anti-
CD4 antibody.    
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Figure 4.2: Cell proportions in blood following administration of anti-CD4 
antibody in naïve BALB/c mice. Naïve BALB/c mice were given i.p. 200 
g/mouse anti-CD4 antibody, blood samples harvested and proportions of B cell, 
CD4 and CD8 T cells, and monocytes calculated on days 3, 7, 14 and 21. *P<0.05 
compared to controls, **P<0.005 compared to controls and ***P<0.0005 compared 
to controls. 
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Figure 4.3: Cell proportions in the spleen following administration of anti-
CD4 antibody in naïve BALB/c mice. Naïve BALB/c mice were given i.p. 200 
g/mouse anti-CD4 antibody, spleens harvested and proportions of B cells, CD4 and 
CD8 T cells, and macrophages calculated on days 3, 7, 14 and 21. *P<0.05 
compared to controls, **P<0.005 compared to controls and ***P<0.0005 compared 
to controls. 
 
4.2.2 Anti-CD20 antibody in BALB/c mice 
Depletion of B cells was investigated in the blood and spleen at various time points 
following a single i.v. administration of 250 g/mouse anti-CD20 antibody in naive 
mice (section 2.3). The time points were days 7, 14 and 21 post administration of 
the antibody. Anti-CD20 antibody was a gift from Dr Dunn and the volume and the 
time points were a recommendation by Dr Dunn. Blood and splenocytes were 
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stained for T cell markers (CD4 and CD8), B cell markers (B220) and monocyte 
markers (F4/80) detailed in section 2.7. CD4 and CD8 T cells, B cells and 
macrophage cell percentages in blood (figure 4.4) and spleen (figure  4.5) were 
calculated and naïve unimmunized mice were used as controls. There was a 
significant reduction in B cell proportions in blood and spleen on all the days 
sampled, the reduction was more pronounced in the spleen than in the blood. In the 
spleen, B cell proportions remained low even at day 21. A reduction in CD4 and CD8 
T cells in the blood were also observed in these mice. 
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Figure 4.4: Cell proportions in blood following administration of anti-CD20 
antibody in naïve BALB/c mice. Naïve BALB/c mice were given i.v. 250 
g/mouse anti-CD20 antibody, blood harvested and proportions of B cell, CD4 and 
CD8 T cells, and macrophages calculated on days 7, 14 and 21. *P<0.05 compared 
to controls, **P<0.005 compared to controls and ***P<0.0005 compared to 
controls. 
Time Points 
%
 L
y
m
p
h
o
c
y
te
s
 
90 
 
CD4 Tcells
Naive Day 7 Day 14 Day 21
0
20
40
60
80
100
CD8 Tcells
Naive Day 7 Day 14 Day 21
0
10
20
30
40
50
B cells
Naive Day 7 Day 14 Day 21
0
20
40
60
80
100
*** *** ***
Macrophages
Naive Day 7 Day 14 Day 21
0
1
2
3
4
5
 
 
Figure 4.5: Cell proportions in spleen following administration of anti-CD20 
antibody in naïve BALB/c mice. Naïve BALB/c mice were given i.v. 250 
g/mouse anti-CD20 antibody, spleen harvested and proportions of B cell, CD4 and 
CD8 T cells, and macrophages calculated on days 7, 14 and 21. *P<0.05 compared 
to controls, **P<0.005 compared to controls and ***P<0.0005 compared to 
controls. 
 
4.2.3 Mitoxantrone in BALB/c mice 
Depletion of cells was investigated in the blood and spleen at various time points 
following a single i.p. administration of 2.5 mg/kg mitoxantrone in naive mice 
(section 2.3). The time points were days 3, 7, 14 and 21 post immunization. The 
volume of mitoxantrone used was extrapolated from the volume used in treating MS 
patients.  Blood and splenocytes were stained for T cell markers (CD4 and CD8), B 
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cell markers (B220) and monocyte markers (F4/80) detailed in section 2.7. CD4 and 
CD8 T cells, B cells and macrophage cell percentages in blood and spleen were 
calculated and naïve unimmunized mice were used as controls. There was a 
reduction in CD4 T cells and B cells in the blood but did not reach a significant level 
(figure 4.6). There was significant reduction in CD4 and CD8 T cell proportions in 
the spleen on days 14 and 21 after administration of mitoxantrone (figure 4.7). 
Macrophages and monocytes were significantly reduced in the spleen and blood. 
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Figure 4.6: Cell proportions in the blood following administration of 
mitoxantrone in naïve BALB/c mice. Naïve BALB/c mice were given i.p. 2.5 
mg/kg mitoxantrone, blood samples harvested and proportions of B cell, CD4 and 
CD8 T cells, and monocytes calculated on days 3, 7, 14 and 21. *P<0.05 compared 
to controls, **P<0.005 compared to controls and ***P<0.0005 compared to 
controls. 
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Figure 4.7: Cell proportions in the spleen following administration of 
mitoxantrone in naïve BALB/c mice. Naïve BALB/c mice were given i.p. 2.5 
mg/kg mitoxantrone, spleens harvested and proportions of B cell, CD4 and CD8 T 
cells, and macrophages calculated on days 3, 7, 14 and 21. *P<0.05 compared to 
controls, **P<0.005 compared to controls and ***P<0.0005 compared to controls. 
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4.3 Discussion 
This chapter details the depletion of different cell subsets of the immune system 
using mitoxantrone or monoclonal antibodies targeting specific cell populations. 
Mitoxantrone, anti-CD4 and anti-CD20 antibodies were administered in naïve 
BALB/c mice to investigate cell subset depletion. Anti-CD4 antibodies significantly 
reduced CD4 T cells in spleen and blood; and anti-CD20 antibody significantly 
reduced B cells in spleen and blood. Mitoxantrone significantly reduced CD4 and 
CD8 T cells in spleen and reduced CD4 T cells and B cells in the blood. It is thought 
that depletion of immune cell populations leads to a reconstitution of naïve cell 
pools. It is hoped that during this reconstitution period, the immune system can be 
reprogrammed.  
 
Depleting anti-CD4 antibodies have been trialed in MS and have shown that CD4 
depletion is long-lasting, however this did not appear to have a beneficial clinical 
outcome on the disease (van Oosten et al., 1997). In the EAE setting, CD4 T cell 
depletion has been shown to prevent the development of EAE (O'Neill et al., 1993) 
and it was shown that CD4 T cell depletion was able to intercept the transition from 
acute-to-chronic EAE when applied to B-cell-deficient animals that just reached the 
peak of disease severity (Hoehlig et al., 2012). Following CD4 T cell depletion, 
reconstitution of these cells was observed in humans (Mackall et al., 1995) and in 
mice (Rice et al., 1995). In my project, a significant reduction in CD4 T cell 
proportions were observed in blood and in spleen on all the days sampled following 
anti-CD4 antibody administration and this was long lasting (21 days). This was also 
observed in MS patients where, CD4 T cells were depleted long term but this did not 
appear to affect the outcome of the disease in these patients (van Oosten et al., 
1997). The proportion of CD4 T cells appeared to be rising on day 21 but had not 
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reached the level observed in the naïve mice. Interestingly, a reduction in B cells in 
the blood was also observed.  
Anti-CD20 antibodies have been used in the treatment of MS and EAE. In MS, 
Rituximab, humanized mouse monoclonal antibody against the human CD20 surface 
molecule has been shown to reduce relapse rates in RR-MS (Bar-Or et al., 2008). 
Rituximab has also been shown to affect the outcome of EAE in mice, depending on 
the time of administration and the animal model used. In this project, B cells were 
significantly reduced in naïve BALB/c over time in blood and spleen and the 
reduction was more striking in the spleen up to 21 days post administration. 
Effective B cell depletion were observed following anti-CD20 administration (Chapter 
5  of this thesis) and in C57BL/6  up to day 57 (DiLillo et al., 2008). B cells are 
depleted in the blood, spleen, lymph nodes and gut-associated lymphoid organs by 
day 7 (Hamaguchi et al., 2005). Anti-CD20 antibody may deplete memory B cells 
some of which are precursors of antibody-secreting plasma cells, thereby reducing 
the sources of new antibody-secreting plasma cells specific for particular antigens 
(in this project the antigen of interest is human recombinant interferon-beta). The 
long-lasting depletion of B cells as well as depletion of mature B cells will be 
relevant in the tolerization strategy discussed in chapter 4 of this thesis. 
Interestingly, we also saw an effect in the proportion of CD4 and CD8 T cells in the 
blood post-treatment, which raises interesting questions and should be studied in 
more detail. 
 
Mitoxantrone has been shown to have a cytotoxic effect in lymphocytes. 
Mitoxantrone depletes several subsets of lymphocytes including CD4 and CD8 T 
cells, B cells and NK cells and then a reconstitution of these populations was 
observed (Piao et al., 2007). Mitoxantrone has a dose-dependent effect on the 
treatment of EAE, it was shown to significantly reduce the severity of acute EAE and 
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prevent the onset of EAE if administered pre-induction (Baker et al., 1992). Clinical 
trials data also suggest efficacy of mitoxantrone in reducing relapses and slowing 
disease progression in relapsing-remitting and secondary progressive MS 
(Debouverie et al., 2007). A nonspecific cytotoxicity effect on lymphocytes is 
believed to be a major mechanism responsible for the clinical effects of 
mitoxantrone in MS patients (Neuhaus et al., 2005). There was a minor reduction in 
CD4 T cells and B cells in the blood but this did not reach a significant level. There 
was significant reduction in CD4 and CD8 T cell proportions in the spleen on days 14 
and 21 after administration of mitoxantrone. Mitoxantrone was not well tolerated by 
the BALB/c mice, and this could be due to the cytotoxic cardiac effect that has been 
described in humans. Once mitoxantrone was administered, the mice were closely 
monitored. 
 
With the successful depletion of various immune cell populations in BALB/c mice, it 
is hoped that the NAbs model (discussed in chapter 3) can be used to study 
strategies for inducing tolerance to human IFN in combination with depletion 
strategies. Neutralizing antibodies to rhIFN will be induced in the BALB/c mice and 
then the immune cells will be depleted and during the start of the recovery period 
rhIFN will be re-introduced via the intravenous route to induce tolerance to the 
antigen. It is hoped that the regeneration and reprogramming of the immune 
system will lead to a regeneration of the natural regulatory events that curb 
autoimmune cells in the MS setting. Once the mechanism of a reconstituting 
immune system is better understood, we may be able to intervene and re-educate 
the immune system, which may pose a treatment strategy for autoimmune diseases 
like MS (Muraro et al., 2006).     
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Chapter 5 
5 Development of Tolerization Strategy 
 
5.1 Introduction 
Immune tolerance can be defined as the ability of the immune system to distinguish 
self from non-self and harmful from harmless molecules. Tolerance is also the 
inability to mount an immune response to a subsequent challenge with a previously 
immunogenic antigen. The route of antigen introduction is critical in determining the 
outcome of an immune response. Intravenous and mucosal administration of 
antigen for example, favours the induction of tolerance to the antigen (Verbeek et 
al., 2007).  
In this project, neutralizing antibodies (NAbs) to recombinant human interferon beta 
(rhIFN) was used as a model human autoimmune disease to test antigen-specific 
immune tolerance strategies (development of the NAbs model discussed in chapter 
3). Depletion of the immune cells by mitoxantrone, anti-CD4 antibody and anti-
CD20 antibody triggers a reconstitution program that leads to renewal of the T cell 
and B cell repertoire (discussed in chapter 4). Within this window of reconstitution 
in the established NAbs model, it was hoped that the immune system can be 
manipulated by re-introducing rhIFN via the intravenous route leading to tolerance 
to the protein.  
 
A breakdown of immune tolerance is thought to be an underlying factor in human 
diseases such as autoimmune diseases. Multiple sclerosis (MS) is a chronic 
neurodegenerative autoimmune disease and the immune system is thought to be a 
key player in the progression of the disease (Bruck, 2005). To date there are no 
definitive treatments which cure MS, but there are several therapies which generally 
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act as immunomodulators or immunosuppressive agents. Treating MS patients by 
immunosuppression over years may be problematic as different subsets of 
lymphocytes are involved in normal immune surveillance; removal of one or more of 
these subsets by selective depletion may be useful in studying and identifying the 
mechanisms involved in tolerance induction. However, opportunistic infection and 
tumouregenesis are some of the clinical consequences that may arise as a result of 
long-term immunosuppression. The “ideal” method in treating autoimmune 
diseases, such as MS, would be an antigen-specific tolerance therapy to silence the 
pathogenic autoimmunity without generalised immunosuppression. In IFN treated 
MS patients with NAbs, it is hoped that induction of tolerance by elimination or 
reduction of NAbs will improve the efficacy and longevity of IFN treatment in these 
patients. 
 
5.1.1 Central tolerance 
Central tolerance is the process by which lymphocytes reactive to self-antigen are 
largely eliminated during development. The main method is by deletion through 
negative selection. In the case of T cells, central tolerance occurs when the bulk of 
self-reactive T cells are deleted during thymic development. T cell development 
occurs in the thymus, were rearrangement of the T cell receptor (TCR) genes occurs 
leading to the diversity of T cell population. During intrathymic development of T 
cells, self-antigen loaded in MHC molecules are present and T cells with TCR that 
bind to these self-antigen undergo one of 2 selections. T cells with low to medium 
affinity for self-antigen receive survival signals that ligate the TCR and leads to 
survival of these T cells termed positive selection (Klein et al., 2009). The other 
selection process termed negative selection leads to apoptosis of T cells with TCR 
with strong affinity for self-antigen, strong enough to have the potential of being 
autoimmune disease mediators. This negative selection process is aided by the 
99 
 
transcription factor Aire. Aire is an autoimmune regulator gene and facilitates the 
thymic expression of tissue specific antigens (Anderson et al., 2011). The ideal 
outcome of this selection process would be a T cell repertoire with TCRs that may 
bind to self-MHC molecules but are unresponsive to self-antigen (Griesemer et al., 
2010).  
 
B cell development occurs in the bone marrow. Primary development of B cells is 
defined by the re-arrangement and expression of immunoglobulin (Ig) genes, these 
are immature B cells which then undergo selection for self-tolerance. Self-reactive B 
cells are deleted in the bone marrow by clonal deletion (Wardemann et al., 2003). 
The surviving B cells leave the bone marrow for the periphery; these B cells are 
immature and have IgM expressed on their cell surface. B cells that survive 
negative selection differentiate to become mature B cells (naive cells) that express 
IgD, IgM and other proteins such as B220 in mice. B220 is expressed in all stages of 
B cell development in the mouse. The final stages of development of B cells take 
place in the spleen (Loder et al., 1999); B cells undergo antigen-dependent 
differentiation into antibody-secreting and/or memory B cells. Developing B cells 
that bind weakly to self-antigen survive through positive selection (Levine et al., 
2000) and their Ig undergoes rearrangement. 
 
5.1.2 Peripheral tolerance 
It has been reported that some of these self-reactive T cells may escape into the 
periphery (Liu et al., 1995). These “escaped” cells may be dangerous as they can 
potentially be recruited to give an autoimmune response. To monitor such 
potentially dangerous cells, a mechanism termed peripheral tolerance is in place to 
prevent these cells from orchestrating an autoimmune attack (Kisielow et al., 1988; 
Walker et al., 2002). Clones of cells that respond to self-antigen are generally 
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deleted preventing the proliferation of these cells in response to the antigen 
(McCaughtry et al., 2008). The key mechanisms that maintain tolerance in the 
periphery include clonal deletion, anergy, ignorance, and regulation. Most cells of 
the immune system require two signals for the activation of the cells; T cells for 
instance require a signal through the TCR as well as a second co-stimulatory 
activation signal(s). The absence of the second activation signal lead to the 
induction of cell death, induction of anergy (a state of unresponsiveness to antigen) 
and robust tolerance (Chen, 2004). T cells can differentiate into different subtypes: 
Th1 cells which are IFN producers and promote intracellular; Th2 cells which 
produce IL4 and IL5 which promote humoural immunity and allergic responses 
(Mosmann et al., 2005). Another subset of T cells is the Th17 T cells which produce 
IL17 and are involved in the control of certain autoimmune or infectious diseases 
(Weaver et al., 2006). Cell activation is delicately counterbalanced by the 
production of regulatory cells some of which appear to be inducible in the periphery; 
these regulatory T cells (T regs) another subset of T cells, are thought to be central 
to peripheral tolerance through their suppressive function (Bach, 2003). T regs 
suppress several cell types including CD4+ helper cells, CD8+ cytotoxic T 
lymphocytes, antibody production by B cells and antigen presenting (APC) function 
(Eddahri et al., 2006; Mempel et al., 2006; Taams et al., 2000). In a subset of T 
regs known as CD25high-FoxP3+ T regs, there is an upregulation of forkshead 
transcription factor (Foxp3) following activation, expression of FoxP3 does not 
always correlate with the suppressive function (Tran et al., 2007). Another subset of 
T regs is the type 1 T regs (Tr1) that are suppressive through the production of high 
levels of IL10 and transforming grown factor beta (TGF) (Groux et al., 1997). Tr1 
cells do not express Foxp3 (Vieira et al., 2004). A third subset of T regs is known as 
Th3 cells, these are regulatory cells that are a result of conversion of naive CD4 T 
cells to inducible T regs by TGF(Chen et al., 2003). Tolerance interventions may 
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boost the numbers and functions of T regs and/or inhibit the activation of naive T 
cells by co-stimulatory blockage (St Clair et al., 2007). 
 
A breakdown in tolerance can lead to an immune response to an antigen that would 
otherwise not elicit an immune response. A breakdown in tolerance to self-antigen 
for example is an underlying thread in many autoimmune diseases; and allergic 
diseases involve an impaired tolerance to otherwise harmless molecules. In MS, 
breaking of tolerance to auto-antigens e.g. myelin basic proteins, is thought to be of 
pathogenic relevance in the clinical outcome (such as lesion distribution) of the 
disease (Greer et al., 2008). 
 
 
5.1.3 Tolerization strategies 
Many strategies for induction of tolerance have been reported in naive immune cells 
including oral, nasal and intravenous route of immunization and high or low dose 
antigen. Memory T cells have less stringent activation requirements than naive cells 
with reduced and in some cases no co-stimulation, as such it can be difficult to 
induce tolerance in mice with memory T cells (Valujskikh, 2006). The intravenous 
(i.v.) route of antigen introduction for instance has been used to boost antibody 
responses and i.v. MOG stimulated a B cell response leading to the exacerbation of 
chronic EAE in marmosets (Genain et al., 1996). The intravenous administration of 
antigen has most consistently induced antigen-specific tolerance in established cell-
mediated autoimmunity or hypersensitivity. Tamura et al successfully induced 
immune tolerance to Factor VIII (FVIII) by continuous infusion of recombinant 
FVIII, without this most haemophilia patients may have limited alternative 
treatment (Tamura et al., 2006). The main mechanisms involved in i.v. induction of 
tolerance are clonal deletion, induction of regulatory T cells and anergy of antigen-
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specific T cells (Jacobs et al., 1994). Improved variations to the i.v. method of 
tolerance induction have also been reported in animal models including cross-linking 
antigen (peptides) to splenocytes with 1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide (ECDI) a cross-linking agent. Cross-linking of splenocytes with 
antigens induces an antigen-specific tolerance in the EAE model which led to 
prevention and treatment of disease in this model. The splenocytes-antigen linked 
tolerance induced was long-lasting and improved tolerance in comparison with 
soluble peptides (Turley et al., 2007). Another method for improving tolerance 
induction is by the depletion of cell subsets prior to i.v. introduction of antigen. In 
the EAE model, it has previously been shown that reduction of cell subset pools 
(CD4 T cell depletion) prior to tolerance induction produced a robust 
unresponsiveness in established EAE disease (Pryce et al., 2005). The reduction of 
cell pools prior to tolerance induction was used in this project as a method to try 
and improve the induction of tolerance to rhIFN in the NAbs model. 
 
The depletion strategies used in this project include CD4 and CD20 depleting 
antibodies, and administration of mitoxantrone. These depletion strategies have 
previously been tested/trialed in EAE models and MS patients. Administration of 
CD4-specific monoclonal antibodies resulted in reduced EAE severity in EAE model 
(Pryce et al., 2005); and in MS patients, treatment resulted in depletion of CD4 T 
cells, however beneficial clinical effects measured by the number of active lesions 
by MRI were lacking (van Oosten et al., 1997). 
Rituximab®, a humanized mouse monoclonal antibody against the human CD20 
surface molecule, has been shown to reduce relapse rate by about 50% in 
relapsing-remitting MS (Bar-Or et al., 2008). EAE severity was reduced in a 
transgenic EAE model treated with Rituximab® prior to immunization or at the 
onset of the clinical signs (Monson et al., 2011). Mitoxantrone, another depletion 
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strategy that was investigated in this project, causes a reduction in CD4 and CD8 T 
cells, macrophages and B cells in the spleen (Piao et al., 2007), and has been 
shown to significantly reduce the severity of acute phase EAE and also can prevent 
the onset of EAE if used pre-infection in a dose-dependent manner (Baker et al., 
1992). Clinical trials data also suggest efficacy of mitoxantrone in reducing relapses 
and slowing disease progression in relapsing-remitting and secondary progressive 
MS (Debouverie et al., 2007).  
All three depletion strategies were incorporated into the tolerization method to 
investigate methods of improving tolerance induction in the NAbs model. 
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5.2 Results 
5.2.1 Induction of neutralizing antibody 
Mice were immunized with recombinant human IFN (Avonex®, Betaferon® or 
Rebif®) in CFA via the sub-cutaneous route (section 2.4); and sera/plasma samples 
collected (section 2.6) and tested in the neutralizing antibody assay (section 2.8). 
The 50% point between maximum and minimum log LCPS (luminescent counts per 
second) was determined and used to calculate the percentage inhibition; titres were 
also calculated for each sample tested (section 2.8.4). Naïve, unimmunized mice 
serum was used as a negative control.  
 
To investigate the background levels of NAbs induction in the NAbs model, BALB/c 
mice (n=8) were immunized sub-cut with 20 g Betaferon® on day 0 and serum 
samples collected and tested in the NAbs assay on day 7.  No NAbs were observed 
in these mice (figure 5.1). BALB/c mice (n=7) were immunized sub-cut with 20 g 
Betaferon® on days 0 and 7 and  serum samples collected and tested in the NAbs 
assay on day 21. NAbs were observed in 5 of the 7 mice tested at this time point 
(figure 5.2). Table 5.1 is a representative graph of NAbs observed on day 35 in this 
project in mice immunized sub-cut with 20 g Betaferon® on days 0, 7 and 21. 
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Figure 5.1: Neutralizing antibodies to Interferon-beta in BALB/c mice. 
BALB/c mice (n=8) were immunized sub-cut with 20 g Betaferon® in complete 
Freund’s adjuvant on day 0 and serum samples collected and tested in the NAbs 
assay on day 7. %inhibition is the percentage of IFN that was inhibited by the 
sample upon incubation. Titres less than 20 were deemed NAbs negative and titres 
between 20 and >320 were deemed positive.  No NAbs to IFN were observed in all 
test mice. 
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Figure 5.2: Neutralizing antibodies to Interferon-beta in BALB/c mice. BALB/c 
mice (n=7) were immunized sub-cut with 20 g Betaferon® in complete Freund’s 
adjuvant on days 0 and 7; serum samples collected and tested in the NAbs assay on 
day 21. Naïve mouse serum was used as a control and was not immunized. 
%inhibition is the percentage of IFN that was inhibited by the sample upon 
incubation. Titres less than 20 were deemed NAbs negative and titres between 20 and 
>320 were deemed positive. NAbs to IFN were observed in 5 of the 7 test mice. 
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 20 g 20 g 20 g 
 %Inhibition Titre %Inhibition Titre %Inhibition Titre 
1 74.8 232.1 27.6 <20 76.5 130.8 
2 64.3 47.7 64.4 53.5 1.0 <20 
3 50.2 <20 67.7 166.0 79.8 102.5 
4 40.4 <20 15.6 <20 48.3 <20 
5 73.1 118.4 71.8 75.9 49.8 <20 
 
Table 5.1: Neutralizing antibodies to Interferon-beta in BALB/c mice. 
BALB/c mice (n=15) were immunized sub-cut with 20 g Betaferon® in complete 
Freund’s adjuvant on days 0, 7 and 21; serum samples collected and tested in the 
NAbs assay on day 35. Naïve mouse serum was used as a control and were not 
immunized. %inhibition is the percentage of IFN that was inhibited by the sample 
upon incubation. Titres less than 20 were deemed NAbs negative and titres between 
20 and >320 were deemed positive. NAbs to IFN were observed in 8 of the 15 test 
mice. 
 
5.2.2 Effects of intravenous recombinant human interferon on NAbs 
induction 
NAbs to rhIFN has been observed on day 35 in BALB/c mice immunized sub-cut 
with 20 g Betaferon® on days 0, 7 and 21 (table 5.1). To investigate the effects of 
i.v. rhIFN on NAbs induction in the NAbs model, BALB/c mice (n=15) were first 
given 12.5 g intravenous Betaferon® per mouse on day -8 and were then 
immunized sub-cut with 20 g Betaferon® on days 0, 7 and 21 and samples were 
analyzed in a NAbs assay on Day 35 to investigate the development of NAbs. NAbs 
to rhIFN were observed in 6 of the 15 mice tested (table 5.2), in comparison with 
mice that were immunized sub-cut without i.v. administration of Betaferon® where 
an average of 50-70% of the samples were NAbs positive. 
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 20 g 20 g 20 g 
 %Inhibition Titre %Inhibition Titre %Inhibition Titre 
1 74.6 39.6 40.9 <20 88.1 66.6 
2 47.4 <20 90.2 130.6 26.4 <20 
3 0 <20 7.2 <20 8.5 <20 
4 17.3 <20 88.4 67.5 26.4 <20 
5 73.9 42.5 73.4 37.3   
 
Table 5.2: Neutralizing antibodies to Interferon-beta in BALB/c mice. 
BALB/c mice (n=15) were given 12.5 g Betaferon® intravenously on day -8 and 
immunized sub-cut with 20 g Betaferon® in complete Freund’s adjuvant on days 0, 
7 and 21; serum samples collected and tested in the NAbs assay on day 35. Naïve 
mouse serum was used as a control and were not immunized. %inhibition is the 
percentage of IFN that was inhibited by the sample upon incubation. Titres less 
than 20 were deemed NAbs negative and titres between 20 and >320 were deemed 
positive. NAbs to IFN were observed in 6 of the 15 test mice. 
 
5.2.3 Effects of depletion and tolerance induction strategies on NAbs 
BALB/c mice (n=40) were immunized sub-cut with 20 g Betaferon® on days 0, 7 
and 21 to induce NAbs to rhIFN, serum samples were tested in the NAbs assay on 
day 35 and NAbs to rhIFN were observed in these mice (figure 5.5). These mice 
were then depleted of immune cells by administration of anti-CD20 or anti-CD4 
antibodies, or with mitoxantrone on day 38, control group had no depletion 
strategy. Anti-mouse CD20 antibody was administered i.v. at 250 g/mouse, 
YTS191 CD4 depleting monoclonal antibody was administered i.p. at 200 g/mouse 
and mitoxantrone administered i.p. at 2.5 mg/kg. All mice were given intravenous 
IFN (Rebif® at 12.5 g/mouse) on day 52. The mice that were given mitoxantrone 
were poorly and had to be discontinued from the study. The other mice were finally 
re-challenged with sub-cut IFN (Betaferon® at 20 g/mouse) on day 55 and all 
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mice culled on day 65 (figure 5.3). NAbs was observed in approximately half of all 
samples tested on day 35 (figure 5.4 and table 5.3).  
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Figure 5.3: Timeline for immunization schedule for the administration of 
interferon-beta, depletion strategy and induction of tolerance in BALB/c 
mice. BALB/c mice (n=30) were immunized sub-cut with 20 g Betaferon® in 
complete Freund’s adjuvant on days 0, 7 and 21; immune cells were depleted on day 
38 by administration of anti-CD20 antibody (n=10 at 250 g/mouse, i.v.), anti-CD4 
antibody (n=10 at 200 g/mouse, i.p.) or no depletion (n=10). All mice were 
administered with i.v. Rebif® (at 12.5 g/mouse) on day 52; all mice were finally 
given 20 g Betaferon® sub-cut on day 55 and samples taken on days 35 and 65. 
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Figure 5.4: Neutralizing antibodies to Interferon-beta in BALB/c mice. 
BALB/c mice (n=30) were immunized sub-cut with 20 g Betaferon® in complete 
Freund’s adjuvant on days 0, 7 and 21; serum samples collected and tested in the 
NAbs assay on day 35. %inhibition is the percentage of IFN that was inhibited by 
the sample upon incubation. NAbs to IFN were observed in 13 of the 30 test mice. 
 
Titres Positive Negative 
<20 
(negative) 
- 14 
20-99 
 
11 - 
100-320 - - 
>320 2 - 
 
Table 5.3: Neutralizing antibodies to Interferon-beta in BALB/c mice. 
BALB/c mice (n=30) were immunized sub-cut with 20 g Betaferon® in complete 
Freund’s adjuvant on days 0, 7 and 21; serum samples collected and tested in the 
NAbs assay on day 35. Titres less than 20 were deemed NAbs negative and titres 
between 20 and >320 were deemed positive. NAbs to IFN were observed in 13 of 
the 30 test mice. 
 
The samples taken on day 65 post tolerance induction were tested in the NAbs 
assay. 5 of the 10 mice in the anti-CD4 treated group were NAbs positive in 
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comparison with the control group (no depletion) and the anti-CD20 treated groups 
which had 3 of 10 mice NAbs positive (figure 5.5 and table 5.4). 
 
Figure 5.5: Neutralizing antibodies to Interferon-beta in BALB/c mice. 
BALB/c mice (n=30) were immunized sub-cut with 20 g Betaferon® in complete 
Freund’s adjuvant on days 0, 7 and 21; immune cells were depleted on day 38 by 
administration of anti-CD20 antibody (n=10 at 250 g/mouse, i.v.), anti-CD4 
antibody (n=10 at 200 g/mouse, i.p.) or no depletion (n=10). All mice were 
administered with i.v. Rebif® (at 12.5 g/mouse) on day 52; all mice were finally 
given 20 g Betaferon® sub-cut on day 55 and serum samples tested in the NAbs 
assay on day 65. %inhibition is the percentage of IFN that was inhibited by the 
sample upon incubation. Titres less than 20 were deemed NAbs negative and titres 
between 20 and >320 were deemed positive. 3 in the Control group and anti-CD20 
treated group were NAbs positive and 5 in the anti-CD4 treated group were NAbs 
positive.  
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 Anti-CD20 Anti-CD4 No Depletion 
 %Inhibition Titre %Inhibition Titre %Inhibition Titre 
1 0 <20 0 <20 78.5 85.1 
2 12.4 <20 39.5 <20 0 <20 
3 73.9 45.3 0 <20 0 <20 
4 0 <20 76.7 127.1 79.0 70.4 
5 76.0 134.7 71.7 42.5 0 <20 
6 0 <20 4.3 <20 0 <20 
7 37.5 <20 9.1 <20 74.2 45.9 
8 33.1 134.8 11.7 42.5 28.2 <20 
9 0 <20 75.3 65.8 0 <20 
10 0 <20 80.7 162.0 0 <20 
 
Table 5.4: Neutralizing antibodies to Interferon-beta in BALB/c mice. Titres 
less than 20 were deemed NAbs negative and titres between 20 and >320 were 
deemed positive. 3 in the Control group and anti-CD20 treated group were NAbs 
positive and 5 in the anti-CD4 treated group were NAbs positive. 
 
5.2.4 Proliferating cells and cytokine production 
Mice were immunized sub-cut with recombinant human IFN (Betaferon®) in CFA 
and splenocytes collected and tested in the proliferation assay (section 2.7.4). Table 
5.5 is a summary of results observed in this section. 
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Immunization 
schedule 
Cytokine results Figure Summary 
CD4 
IFN 
CD8 
IFN 
Multiple immunization only 
Sub-cut  Betaferon ++ 
(Day 7) 
     - 5.6 
 
5.7 
Significant IFN and 
IL-17 in CD4 and 
CD8 T cells  
 
Intravenous administration 
I.v. Betaferon (12.5-
750 g) post multiple 
immunizations  
 
+ 
 
+ 
5.8 
 
5.9 
CD4 T cell 
proliferation 
reduced. IFN 
unaltered in CD4 
and CD8 T cells 
I.v. Betaferon (12.5 
g) post immunization 
 
+ 
 
+ 
5.10 IFN in 25% of test 
samples 
I.v. Betaferon 
(12.5g) post multiple 
immunizations 
 
+ 
 
++ 
5.11 IFN more in CD8 
than CD4 T cells 
I.v. Betaferon 
(12.5g) pre and post 
multiple immunizations 
 
+ 
 
+ 
5.12 
 
5.13  
IFN in CD8 and CD4 
T cells in 80% of 
test samples 
 
Depletion Strategies 
Multiple immunization 
+ anti-CD4 depletion + 
i.v. Betaferon 
 
+ 
 
+ 
 
5.14 
IFN more in CD8 
than CD4 T cells  
Multiple immunization 
+ anti-CD20 depletion 
+ i.v. Betaferon 
 
+ 
 
+ 
 
5.15 
IFN more in CD8 
than CD4 T cells 
Multiple immunization 
+ no depletion + i.v. 
Betaferon 
 
+ 
 
+ 
 
5.16 
IFN more in CD8 
than CD4 T cells 
 
Table 5.5: Summary of Cytokine responses observed following different 
immunization schedules. 
 
To investigate the background levels of proliferation and cytokine production in CD4 
and CD8 T cells in the NAbs model, BALB/c mice (n=15) were immunized sub-cut 
with 20 g Betaferon® on day 0, 7 and 21, splenocytes were collected and tested in 
the proliferation assay 7 days post each immunization (days 7, 14 and 28). rhIFN 
specific proliferation and IFN production were observed in CD4 T cells in mice 
immunized on day 0, 7 and 21 (figure 5.7). Figure 5.6 shows representative plots 
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observed.   CD4 T cells were proliferating in response to rhIFN and were producing 
IFN at all-time points investigated. Proliferation was also observed in CD8 T cells 
but no rhIFN-specific IFN production were observed in these subset of cells. IL-17 
production was also investigated in CD4 and CD8 proliferating T cells (figure 5.8). 
CD4 and CD8 T cells were proliferating and producing IL-17 in response to rhIFN 
following day 0 immunization. The rhIFN specific IL-17 responses appear to have 
been lost or reduced following subsequent immunizations. 
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Figure 5.6: CD4 and CD8 T cell IFN production. Flow cytometry analysis of CD4 
and CD8 T cell population in NAbs mice. Splenocytes were stained for CD4 or CD8 T 
cell markers; CD4 and CD8 T cells were gated in the lymphoid population to 
determine proportions producing IFN in response to rhIFN.    
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Figure 5.7: Interferon-beta specific proliferation and interferon-gamma 
production in BALB/c mice. BALB/c mice (n=15) were immunized sub-cut with 20 g 
Betaferon® in complete Freund’s adjuvant on days 0, 7 and 21; splenocytes were collected 
and tested in the proliferation assay 7 days post each immunization. Proliferating CD4 and 
CD8 T cells were gated and proportions producing IFN were analysed for each test mice. The 
graph shows an average of the test mice at each time immunization time point. Proliferating 
CD4 T cells were producing IFN on days 0, 7 and 21 in response to rhIFN; day 7 showing 
the most marked response. Significance of P<0.05 (*), P<0.01(**) or P<0.001(***) in 
comparison with no antigen control. 
 
Figure 5.8: Interferon-beta specific proliferation and interleukin-17 
production in BALB/c mice. BALB/c mice (n=15) were immunized sub-cut with 20 g 
Betaferon® in complete Freund’s adjuvant on days 0, 7 and 21; splenocytes were collected 
and tested in the proliferation assay 7 days post each immunization. Proliferating CD4 and 
CD8 T cells were gated and proportions producing IL-17 were analysed for each test mice. 
The graph shows an average of the test mice at each time immunization time point. 
Proliferating CD4 and CD8 T cells were producing IL-17 on day 0 in response to both heat-
inactivated (IFN HI) and the natural IFN. Significance of P<0.05 (*), P<0.01(**) or 
P<0.001(***) in comparison with no antigen control. 
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5.2.5 Effects of intravenous recombinant human interferon on proliferating 
T cells 
rhIFN specific proliferation and cytokine production were observed in CD4 and CD8 
T cells from mice immunized with Betaferon® on days 0, 7 and 21. To investigate 
the influence of i.v. rhIFN on these cells in the NAbs model, BALB/c mice were 
immunized sub-cut with 20 g Betaferon® on days 0, 7 and 21 and given i.v. 
Rebif® at various concentrations (12.5 – 750 g/mouse) on day 39. The control 
group was not given i.v. Rebif®. A large proportion of CD4 T cells in the control 
group were proliferating in comparison with the test groups (figure 5.9). rhIFN 
specific IFN production in proliferating CD4 T cells were observed in all groups 
including the control group (figure 5.10).  
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Figure 5.9: CD4 T cell proliferation in BALB/c mice. BALB/c mice (n=42) were 
immunized with 20 g Betaferon® in complete Freund’s adjuvant on days 0, 7 and 21; 
then given i.v. Rebif® at various concentrations (0-750 g/mouse) on day 39 and finally 
immunized 20 g/mouse sub-cut Betaferon® on day 42. Splenocytes were collected and 
tested in the proliferation assay on day 52. Proliferating CD4 and CD8 T cells were gated 
and analysed for each pooled group. In the control group (no i.v. Rebif®), a larger 
proportion of CD4 T cells were proliferating in comparison with the groups given i.v. 
Rebif®. Conditions: 1=No Antigen, 2=IFN heat-inactivated and 3= IFN. 
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Figure 5.10: Interferon-beta specific CD4 T cell proliferation and IFN 
production in BALB/c mice. BALB/c mice (n=42) were immunized with 20 g 
Betaferon® in complete Freund’s adjuvant on days 0, 7 and 21; then given i.v. Rebif® 
at various concentrations (0-750 g/mouse) on day 39 and finally immunized 20 
g/mouse sub-cut Betaferon® on day 42. Splenocytes were collected and tested in the 
proliferation assay on day 52. Proliferating CD4 and CD8 T cells were gated and IFN 
production analysed for each pooled group. rhIFN specific IFN production was 
observed in the groups that received i.v. Rebif and also in the control group. Conditions: 
1=No Antigen, 2=IFN heat-inactivated and 3= IFN.  
 
To further investigate the effects of intravenous administration of rhIFN on 
proliferative responses of CD4 and CD8 T cells, BALB/c mice (n=16) were 
immunized sub-cut with 20 g Betaferon® on day 0, 7 and 21. All mice were given 
i.v Rebif® at 12.5 g/mouse on day 37 and half the mice (n=8) were culled and 
splenocytes tested in the proliferation assay on day 42. CD4 and CD8 T cells 
proliferative responses were observed in 2 of these 8 test mice (figure 5.11). The 
other half (n=8) were immunized sub-cut with 20 g/mouse Betaferon® on day 40 
to see if further immunization would affect the outcome of the T cells responses. 
Splenocytes were collected and tested in the proliferation assay on day 50; CD4 T 
cell responses were observed in 1 test mouse and 5 test mice showed CD8 T cell 
proliferative responses to rhIFN (figure 5.12), these responses did not reach a 
significant level. 
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A) 
 
B) 
 
Figure 5.11: Interferon-beta specific proliferation in BALB/c mice. BALB/c 
mice (n=8) were immunized sub-cut with 20 g Betaferon® in complete Freund’s 
adjuvant on days 0, 7 and 21; then given i.v. Rebif® at 12.5 g/mouse on day 37. 
Splenocytes were collected and tested in the proliferation assay on day 42. 
Proliferating CD4 and CD8 T cells were gated and analysed for each test mouse. 
rhIFN specific CD4 and CD8 T cell proliferation was observed in 2 of the 8 mice 
tested. A) CD4 T cell proliferation, B) CD8 T cell proliferation. 
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Figure 5.12: Interferon-beta specific proliferation in BALB/c mice. BALB/c 
mice (n=8) were immunized sub-cut with 20 g Betaferon® in complete Freund’s 
adjuvant on days 0, 7 and 21; then given i.v. Rebif® at 12.5 g/mouse on day 37 
and finally immunized 20 g/mouse sub-cut Betaferon® on day 40. Splenocytes 
were collected and tested in the proliferation assay on day 50. Proliferating CD4 and 
CD8 T cells were gated and analysed for each test mouse. rhIFN specific CD4 T cell 
proliferation was observed in 1 test mouse and CD8 proliferation observed in 5 of 
the 8 test mice. A) CD4 T cell proliferation, B) CD8 T cell proliferation. 
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To investigate further the effect of i.v. rhIFN on proliferating cells, BALB/c mice 
(n=10) were first given 12.5 g intravenous Betaferon® per mouse on day -8 and 
immunized sub-cut with 20 g/mouse Betaferon® on days 0, 7 and 21. One group 
was given 12.5 g i.v Rebif® (group A) and the other group was given 125 g i.v. 
Rebif® (group B) on day 39 and both groups were rechallenged with 20 g/mouse 
IFN (Betaferon®) sub-cut on day 43. In group A, 4 of the test mice showed CD4 
and CD8 T cell responses specific for rhIFN (figure 5.13). Similar results were 
observed in Group B (figure 5.14). Increasing the amount of Rebif® given i.v. did 
not appear to dramatically affect the numbers with CD4 and CD8 T cell proliferation 
responses once they have been established.  
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Figure 5.13: Interferon-beta specific T cell proliferation in BALB/c mice. 
BALB/c mice (n=5) were given 12.5 g intravenous Betaferon® per mouse on day -
8 and immunized with 20 g Betaferon® in complete Freund’s adjuvant on days 0, 
7 and 21; then given i.v. Rebif® at 125 g/mouse on day 39 and finally immunized 
with 20 g/mouse sub-cut Betaferon® on day 43. Splenocytes were collected and 
tested in the proliferation assay on day 53. Proliferating CD4 and CD8 T cells were 
gated and analysed for each test sample. rhIFN specific CD4 and CD8 T cell 
proliferation were observed in 4 of the 5 test samples analysed. A) CD4 T cells 
proliferation, B) CD8 T cells proliferation. 
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Figure 5.14: Interferon-beta specific T cell proliferation in BALB/c mice.  
BALB/c mice (n=5) were given 12.5 g intravenous Betaferon® per mouse on day -
8 and immunized with 20 g Betaferon® in complete Freund’s adjuvant on days 0, 
7 and 21; then given i.v. Rebif® at 12.5 g/mouse on day 39 and finally immunized 
with 20 g/mouse sub-cut Betaferon® on day 43. Splenocytes were collected and 
tested in the proliferation assay on day 53. Proliferating CD4 and CD8 T cells were 
gated and analysed for each test sample. rhIFN specific CD4 and CD8 T cell 
proliferation were observed in 4 of the 5 test samples analysed. A) CD4 T cells 
proliferation, B) CD8 T cells proliferation. 
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5.2.6 Effects of depletion and tolerance induction strategies on 
proliferating T cells. 
BALB/c mice were immunized with 20 g Betaferon® on days 0, 7 and 21 to induce 
NAbs to rhIFN. These mice were then depleted of immune cells by administration 
of anti-CD20 or anti-CD4 antibodies, or with mitoxantrone on day 38, control group 
had no depletion strategy. Anti-mouse CD20 antibody was injected i.v. at 250 
g/mouse, YTS191 CD4 depleting monoclonal antibody was injected i.p. at 200 
g/mouse and mitoxantrone injected i.p. at 2.5 mg/kg (section 2.3). All mice were 
given intravenous IFN (Rebif® at 12.5 g/mouse) on day 52. The mice that were 
given mitoxantrone did not tolerate the drug and exhibited sickness behavior and 
had to be discontinued from the study. The other mice were finally rechallenged 
with sub-cut IFN (Betaferon® at 20 g/mouse) on day 55 and all mice culled on 
day 65 and tested in the proliferation assay. In the anti-CD4 depletion group, CD4 T 
cell responses were observed in 2 of the 9 test mice and CD8 T cells responses 
specific for rhIFN were observed in 7 of the 9 test mice (figure 5.15). 5 of the 9 
test mice in the group with anti-CD20 depletion strategy showed CD4 and CD8 T 
cell responses specific to rhIFN (figure 5.16). In the control group with no 
depletion strategy rhIFN specific CD8 T cell responses were observed in all test 
mice and 6 showed CD4 T cell proliferation in response to rhIFN (figure 5.17). 
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Figure 5.15: Interferon-beta specific T cell proliferation in BALB/c mice.  
BALB/c mice (n=10) were immunized with 20 g Betaferon® in complete Freund’s 
adjuvant on days 0, 7 and 21; immune cells were depleted on day 38 by 
administration of anti-CD4 antibody at 200 g/mouse, i.p. All mice were 
administered with i.v. Rebif® (at 12.5 g/mouse) on day 52; all mice were finally 
given 20 g Betaferon® sub-cut on day 55 and splenocytes tested in the 
proliferation assay on day 65. rhIFN specific CD4 and CD8 T cell proliferation were 
observed in 2 (CD4 T cells) and in 7 (CD8 T cells) of the test samples analysed. A) 
CD4 T cells proliferation, B) CD8 T cells proliferation. 
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Figure 5.16: Interferon-beta specific T cell proliferation in BALB/c mice.  
BALB/c mice (n=10) were immunized with 20 g Betaferon® in complete Freund’s 
adjuvant on days 0, 7 and 21; immune cells were depleted on day 38 by 
administration of anti-CD20 antibody at 250 g/mouse, i.v. All mice were 
administered with i.v. Rebif® (at 12.5 g/mouse) on day 52; all mice were finally 
given 20 g Betaferon® sub-cut on day 55 and splenocytes tested in the 
proliferation assay on day 65. rhIFN specific CD4 and CD8 T cell proliferation were 
observed in 1 (CD4 T cells) and in 4 (CD8 T cells) of the test samples analysed. A) 
CD4 T cells proliferation, B) CD8 T cells proliferation. 
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Figure 5.17: Interferon-beta specific T cell proliferation in BALB/c mice. 
BALB/c mice (n=10) were immunized with 20 g Betaferon® in complete Freund’s 
adjuvant on days 0, 7 and 21; no depletion strategy administered on day 38. All 
mice were administered with i.v. Rebif® (at 12.5 g/mouse) on day 52; all mice 
were finally given 20 g Betaferon® sub-cut on day 55 and splenocytes tested in 
the proliferation assay on day 65. rhIFN specific CD4 and CD8 T cell proliferation 
were observed in 5 (CD4 T cells) and in 9 (CD8 T cells) of the test samples 
analysed. A) CD4 T cells proliferation, B) CD8 T cells proliferation. 
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5.3 Discussion 
NAbs to recombinant human interferon beta has been successfully established in the 
BALB/c mice and was termed the NAbs model. This chapter details the strategies 
investigated in this model to induce tolerance to rhIFN. The strategies investigated 
were depleting immune cells followed by re-introduction of rhIFN via the 
intravenous route in the NAbs model. NAbs to rhIFN and proliferative responses of 
CD4 and CD8 T cells were used as indicators for tolerance induction. This chapter 
demonstrates that a combination of depleting immune cells and i.v. re-introduction 
of rhIFN in the NAbs model reduced the incidence of NAbs and CD4 and CD8 T cell 
responders in the combination strategy group. 
 
In the NAbs model, NAbs to rhIFN was established by sub-cut administration of the 
protein and rhIFN-specific CD4 and CD8 T cells proliferative responses and 
cytokine (IFN and IL-17) production were also detected at the time of NAbs 
formation. Intravenous administration of antigen to naïve cells favours the induction 
of tolerance to the antigen. In my project, i.v. rhIFN in naïve BALB/c mice resulted 
in a reduction in the incidence of NAbs. On the other hand, i.v. rhIFN in the early 
phase of established NAbs model did not appear to affect the incidence of NAbs. It 
has been shown that tolerance induction by intravenous administration of antigen 
leads to an increase in the IgG levels (Verbeek et al., 2007). In the NAbs model, it 
is most likely that prior immunization with rhIFNresults in the development of 
mature rhIFN-specific B cell and intravenous administration of rhIFNleads to 
relocation of the antigen to the spleen where the primed B cells can rapidly respond. 
T cell responses were observed in the NAbs model, intravenous administration of 
rhIFNled to a reduction of 70-80% in rhIFN-specific proliferative CD4 T cell 
responses in this model.  
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In established NAbs model, giving i.v. rhIFNprior to induction of NAbs did not 
appear to affect the outcome of CD4 and CD8 T cell rhIFNspecific responses in 
these mice. It could be that the amount of protein given was too low to establish 
tolerance. These mice were given a second round of i.v. rhIFNat a high and low 
dose but this did not reduce the incidence of established T cell responses. In an 
adoptive transfer model, i.v. introduction of antigen resulted in an induction in 
tolerance, with high dose antigen inducing tolerance quicker than low dose antigen 
(Hayashi et. al, 2002). In my project, i.v. rhIFN in established NAbs model led to a 
reduction in antigen-specific proliferative responses by CD4 and CD8 T cells. 
Tolerance induction was not affected by the dose of antigen given as a range of low 
to high i.v. antigen resulted in reduction in CD4 and CD8 T cell proliferative 
responses.   
The depletion strategies used in this project include CD4 and CD20 depleting 
antibodies, and administration of mitoxantrone. All 3 depletion strategies reduced 
cell pools when administered in naïve BALB/c mice; anti-CD4 antibodies significantly 
reduced CD4 T cells in spleen and blood, anti-CD20 antibody significantly reduced B 
cells in spleen and blood, and mitoxantrone significantly reduced CD4 and CD8 T 
cells in spleen and reduced CD4 T cells and B cells in the blood (discussed in chapter 
4). All three depletion strategies were incorporated into the tolerization method to 
investigate methods of improving tolerance induction in the NAbs model. Depletion 
of immune cells generally leads to a reconstitution of  cell pools and during this 
window, it is hoped that the naïve pool can be orchestrated or influenced regarding 
a specific antigen by the route of administration of the antigen. Once NAbs was 
established, the immune cells were depleted and rhIFNre-introduced 
intravenously. The average incidence of NAbs in the NAbs model is between 50 and 
100% and depletion of CD4+ and CD20+ cells prior to intravenous administration of 
rhIFNled to a reduction in the incidence of NAbs to between 30 and 50%. 
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Intravenous administration of rhIFNalone reduced the incidence of NAbs to 30%. 
It appears that intravenous administration of the antigen led to the reduction in 
NAbs incidence and depletion of the cell subsets did not significantly affect the 
outcome of the incidence of NAbs. Depletion of cells subsets however appeared to 
influence T cell responses observed. In the non-depleted control group, more 
animals were proliferating in response to rhIFN, though none reached significance. 
In the group depleted of CD4 T cell, there was an increase of CD8 T cell responses; 
this could be as a result of a reduction in mature CD4 T cells and the naïve pool 
being slowly replenished while the CD8 T cell mature pool was primed and ready to 
respond to the antigen. In the CD20 depleted group, reduction in CD4 and CD8 T 
cell responses observed could be due to the loss of B cells which have co-
stimulatory molecules for T cell activation. 
 
In the NAbs model, intravenous rhIFN can induce tolerance in established T cell 
response. This is most likely as a result of apoptosis of memory T cells due to 
exposure to antigen without the appropriate co-stimulatory signals required. 
Incidence of NAbs was reduced by intravenous antigen. Depletion of immune cell 
pools prior to intravenous antigen reduced the incidence of NAbs and also reduced 
the numbers of CD4 and CD8 T cell antigen-specific responders. The depletion and 
tolerization strategy used in the NAbs model here could be applied to NAbs positive 
patients where the ideal clinical outcome would be an increase or prolonging in the 
efficacy of IFN treatment in these patients. It is hoped that the regeneration and 
reprogramming of the immune system will lead to a regeneration of the natural 
regulatory events that curb autoimmune cells in the MS setting. Once the 
mechanism of a reconstituting immune system is better understood, we may be 
able to intervene and re-educate the immune system, which may pose a treatment 
strategy for autoimmune diseases like MS.  
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Chapter 6 
6 Experimental autoimmune encephalomyelitis and depletion strategy 
 
6.1 Introduction 
Multiple sclerosis (MS) is a chronic neurodegenerative disease and the major cause 
of neurological disability in young adults (Noseworthy et al., 2000). The immune 
system is thought to be a key player in the progression of the disease (Bruck, 
2005); this is supported by the current immunosuppressive and anti-inflammatory 
therapies that slow progression of disease and reduce clinical symptoms (Menge. et 
al., 2008).  
 
To date there are no definitive treatments which cure MS, but there are several 
therapies for reducing relapse rate and severity of clinical outcome of disease. 
These include Interferon-beta, mitoxantrone and several monoclonal antibodies 
including anti-CD20 and anti-CD52.  
 
6.1.1 Experimental autoimmune encephalomyelitis 
Experimental autoimmune encephalomyelitis (EAE) is a widely used autoimmune 
model of MS. EAE can be induced by immunization of EAE models with several 
central nervous system (CNS) peptides such as myelin associated glycoprotein 
(MAG), myelin oligodendrocyte glycoprotein (MOG) and proteolipid protein 1 (PLP1); 
and by spinal cord homogenates (Baker et al., 1990b).  
 
EAE is thought to be a T cell mediated disease as EAE can be induced by adoptive 
transfer of reactive EAE T cells (Pryce et al., 2005). T helper 1 cells (Th1) cells have 
long been regarded as the mediators, but recently T helper 17 cells (Th17) have 
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also been shown to play an important role (Batoulis et al., 2010). However, recent 
evidence highlights the importance of B cells in the development of EAE and MS. 
Autoantibodies have been detected in the cerebrospinal fluid of many MS patients, 
these antibodies have been against a number of antigens (Kanter et al., 2006).  
Mature B cells have been found to cross the blood brain barrier in MS patients and 
may undergo restimulation within lesions (Magliozzi et al., 2007). Abnormal B cell 
responses to cytokines have also been reported in MS patients(Smith-Jensen et al., 
2000). B cells may contribute to the development of EAE by the production of auto-
reactive antibodies and by the presentation of antibodies to T cells. 
Depletion of B cells with Rituximab (a humanized mouse monoclonal antibody 
against human CD20 surface molecule) has shown that B cells are pivotal for the 
development of EAE in a number of mouse models (Monson et al., 2011). Rituximab 
has been shown to reduce relapse rate in RR-MS patients (Hauser et al., 2008).   
EAE models have helped in the development of several drugs for the treatment of 
MS including Glatiramer acetate (GA) (Arnon et al., 1989), Natalizumab (Yednock et 
al., 1992) and mitoxantrone (Piao et al., 2007). The EAE model however does not 
predict clinical outcomes or toxicity in humans; as such the real strength of the EAE 
model is a pre-screen for potential drug treatments for MS (Steinman et al., 2006). 
 
The mouse is the most common specie used in EAE studies; other species have also 
been successfully used including rats, guinea pigs and marmosets. The type of EAE 
disease developed and the pathology observed depends on the strain of mouse used 
and also the antigen used to induce the disease. For instance in the Lewis rat, a 
single acute phase disease is observed and in the C57/BL6 mice acute progressive 
disease is observed. In the Biozzi antibody high (ABH) mouse, immunization with 
whole spinal cord homogenate in complete Freund’s adjuvant leads to a chronic 
relapsing-remitting disease with secondary progression (Baker et al., 1990b), when 
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this strain is immunized with myelin oligodendrocyte glycoprotein (MOG) 35-55 
peptide, a chronic progressive disease with little or no remission is observed (Amor 
et al., 2005). The disease phenotype observed in the ABH mouse (relapsing-
remitting with secondary progression) are similar to the types of disease seen in 
most MS patients; this indicates that the ABH mouse strain may be a relevant EAE 
strain for investigating potential therapeutic treatments for MS disease. 
 
6.1.2 Anti-CD4 antibody in EAE 
CD4 is a marker found on a subset of T cells in the immune system. CD4 antibodies 
were extensively studied as a tool to modify the pathogenesis of EAE and gain a 
greater understanding of the inflammatory components of the disease. CD4-specific 
monoclonal antibody (mAb) suppress T cell dependent responses and have been 
shown to prevent the development of neurological EAE (O'Neill et al., 1993). 
Administration of YTS191.1 (CD4-specific mAb) led to a rapid reduction of CD4+ T 
cells in the peripheral blood and lymphoid tissue by a complement mediated 
mechanism (Cobbold et al., 1984). The basis of CD4-specific mAb 
immunomodulation is not completely understood but it is thought to prevent the 
function of activated effector cells (Sedgwick et al., 1986). YTS177, a non-depleting 
CD4 mAb, results in the down regulation of CD4 and thus cannot cause interaction 
of CD4 with MHC class II antigens, which is required for T cell activation following 
engagement of the TCR with the MHC antigen complex (O'Neill et al., 1993).  
 
6.1.3 Anti-CD20 antibody in EAE 
CD20 is a surface marker found on mature B cells and the marker is lost during 
differentiation into plasma cells. CD20 is not found on pre-B cells, these then 
differentiate into antibody producing cells.  
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Rituximab is a humanized mouse monoclonal antibody against the human CD20 
surface molecule expressed by B cells. Rituximab® depletes a subpopulation of B 
cells (pre-B and mature B cells) without affecting antibody production and secretion 
(Petereit et al., 2008). Rituximab® has been shown to reduce relapse rate by about 
50% in relapsing-remitting MS (Bar-Or et al., 2008).  
In mice, it has been shown that Rituximab depletes B cells in the peripheral blood, 
secondary lymphoid organs and in the central nervous system (CNS). EAE severity 
was reduced in a transgenic EAE model treated with Rituximab prior to 
immunization or at the onset of the clinical signs (Monson et al., 2011). 
 
6.1.4 Mitoxantrone in EAE 
Mitoxantrone is an anthracenedione which acts by intercalating into the DNA 
molecule, it also interferes with RNA, and uncoiling and repair of damaged DNA by 
inhibiting topoisomerase II enzyme (Fox, 2006). Mitoxantrone acts in a dose-
dependent manner and is a potent immunosuppressive agent which inhibits in vivo 
induced proliferative response (Baker et al., 1992). Clinical trials data suggest 
efficacy of mitoxantrone in reducing relapses and slowing disease progression in 
relapsing-remitting and secondary progressive MS (Debouverie et al., 2007). A 
nonspecific cytotoxicity effect on lymphocytes is believed to be a major mechanism 
responsible for the clinical effects of mitoxantrone in MS patients. 
Mitoxantrone causes a reduction in CD4, CD8 and B cells in the spleen (Piao et al., 
2007), and has been shown to significantly reduce the severity of acute phase EAE 
and also can prevent the onset of EAE if used pre-infection in a dose-dependent 
manner (Baker et al., 1992). 
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6.2 Results 
6.2.1 Anti-CD20 antibody depletes B cells in the blood and spleen 
Depletion of B cells was investigated in the blood and spleen at various time points 
following a single i.v. treatment of naive unimmunized ABH mice with 250 g anti-
CD20 antibody (section 2.3). The time points were days 7, 14 and 21 post 
immunization; blood and splenocytes were stained for B cell markers (B220) 
detailed in section 2.7.1. B cell percentages in spleen and blood were calculated 
(Figure 6.1 and 6.2). Reduction in B cells proportion was detected in the spleen and 
in blood up to day 21 post administration of anti-CD20. To ensure that B cells were 
maximally depleted before onset of EAE in the ABH mice, anti-CD20 antibody was 
given to the mice at least 3 days before the expected clinical signs of disease.  
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Figure 6.1: Percentage B cells in blood from ABH mice immunized 
intravenously with anti-CD20 antibody. Each mouse was given 250 g/ml anti-
CD20 i.v. and cardiac bleeds taken on Days 7, 14 and 21 (n=7). The results show B 
cell percentages in lymphocyte population analysed. . *P<0.05 compared to naive. 
 
* * * 
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Figure 6.2: Percentage B cells in spleen of ABH mice immunized 
intravenously with anti-CD20 antibody. Each mouse was given 250g/ml anti-
CD20 i.v. and spleens taken on Days 1, 3, 7, 16 and 21 (n=7). Splenocytes were 
stained for B cell markers. The results show B cell percentages in lymphocyte 
population analysed. ***P<0.0005 compared to naive. 
 
6.2.2 B cell proportions similar in anti-CD20 treated and untreated mice 
following EAE induction 
B cell proportions were measured in terminal blood samples at the end of relapse-
remitting EAE in the ABH mice. This was done to investigate the long term effect of 
anti-CD20 treatment on the B cell proportions. The treated group was given anti-
CD20 antibody either at acute only or at the acute and relapse phases of the 
disease and the untreated group was used as a control (figure 6.3). Similar B cell 
proportions were observed in both the treated and untreated groups (figure 6.4). 
 
*** *** *** 
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Figure 6.3: Timeline for immunization schedule for the administration of 
anti-CD20 antibody in EAE induced mice. 
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Figure 6.4: Percentage B cells in blood of ABH mice post relapse EAE. EAE 
was induced with spinal cord homogenate in complete Freund’s adjuvant on days 0 
and 7 and relapse induced on day 28. Mice were treated with 250g/ml anti-CD20 
i.v on day 8 (acute only group) and day 29 (acute+relapse group) and the control 
group was untreated. Terminal cardiac bleed were taken and cells stained for B cell 
markers. The results show B cell percentages in lymphocyte population analysed. 
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6.2.3 Acute anti-CD20 treatment does not alter EAE severity 
Pre-treatment with anti-CD20 antibody has been shown to alter EAE severity in a 
recombinant mouse model (Monson et al., 2011). The effect of anti-CD20 treatment 
on the severity of EAE was investigated in the ABH mouse.  The mice were treated 
with 250 g anti-CD20 on day 8 prior to the onset of acute EAE (figure 6.3). In 
these mice, the severity of EAE was similar to those observed in the untreated 
group (figure 6.5). There was no significant differences between the untreated and 
anti-CD20 treated groups in the maximal EAE score day of onset of clinical signs or 
the number of mice with EAE (table 6.1). 
 
5 10 15 20 25 30
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
untreated
Anti-CD20
 
Days post EAE induction
M
e
a
n
 C
li
n
ic
a
l 
s
c
o
r
e
 ±
 S
E
M
 
Figure 6.5: Treatment of relapsing remitting EAE with anti-CD20 antibody. 
EAE was induced with spinal cord homogenate in complete Freund’s adjuvant on 
days 0 and 7. Animals were given 250 g/ml anti-CD20 antibody on day 8. The 
results represent the mean ± SEM daily score (n=10). 
  
Treatment 
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Treatment Dose No. EAE/Total Max EAE Score 
±SEM 
Day of onset 
±SEM 
 
Untreated - 9/10 3.8 ± 0.3 17.7 ± 1.3 
Anti-CD20 250 g 9/10 3.9 ± 0.2 16.0 ± 1.1 
Table 6.1: Treatment of relapsing remitting EAE with anti-CD20 antibody. 
EAE was induced with spinal cord homogenate in complete Freund’s adjuvant on 
days 0 and 7. Animals were given 250 g/mouse anti-CD20 antibody on day 8. The 
results represent the mean maximal score of animals that developed EAE, the 
number of animals that developed EAE and the day of onset of clinical signs. 
 
6.2.4 Therapeutic anti-CD20 treatment does not alter EAE relapse 
The effect of anti-CD20 treatment in established EAE was investigated. 250 g of 
anti-CD20 was given to each mouse on day 29 following established EAE symptoms 
and prior to the onset of a relapse (figure 6.3). Severity of EAE in anti-CD20 treated 
group was similar to that observed in untreated group (figure 6.6). The maximal 
score and the number of animals that developed EAE were similar in the treated and 
control group. Although it was observed that therapeutic treatment with anti-CD20 
did not appear to alter EAE relapse, the treatment led to a lengthening of the 
average day of onset of disease (table 6.2). 
 
 
 
139 
 
5 10 15 20 25 30 35 40 45 50
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
untreated
Anti-CD20
 
Days post EAE induction
M
e
a
n
 C
li
n
ic
a
l 
s
c
o
r
e
 ±
 S
E
M
 
Figure 6.6: Treatment of relapsing remitting EAE with anti-CD20 antibody. 
EAE was induced with spinal cord homogenate in complete Freund’s adjuvant on 
days 0 and 7, and a relapse induced on day 29. Animals were given 250 g/ml anti-
CD20 antibody on day 28. The results represent the mean ± SEM daily score 
(n=10). 
 
Treatment Dose No. EAE/Total Max EAE Score 
±SEM 
Day of onset 
±SEM 
 
Untreated - 6/9 3.8 ± 0.4 38.8 ± 1.8 
Anti-CD20 250 g 8/9 3.6 ± 0.5 41.3 ± 1.8 
 
Table 6.2: Treatment of relapsing remitting EAE with anti-CD20 antibody. 
EAE was induced with spinal cord homogenate in complete Freund’s adjuvant on 
days 0 and 7, and a relapse induced on day 29. Animals were given 250 g/mouse 
anti-CD20 antibody on day 28. The results represent the mean maximal score of 
animals that developed EAE and the day of onset of clinical signs in the relapse 
phase. 
 
  
Treatment 
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6.2.5 Multiple anti-CD20 treatment does not significantly alter EAE 
severity 
Single treatment with anti-CD20 in established EAE pre-acute or pre-relapse did not 
alter the severity of EAE in the ABH model. The effect of multiple treatments with 
anti-CD20 in established EAE was explored. The mice were each given 250 g anti-
CD20 antibody pre-acute and pre-relapse on days 8 and 28; and the control group 
was untreated (figure 6.3). There was essentially no reduction in severity of EAE in 
the treated group in comparison with the untreated group in both the acute and the 
relapse phases of the disease (figure 6.7). Likewise there was no significant 
reduction in the number of mice with EAE observed in the relapse phase in the 
treated group in comparison with the untreated group; similar maximal scores and 
day of onset of disease was observed in both groups (table 6.3). 
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Figure 6.7: Treatment of relapsing remitting EAE with anti-CD20 antibody. 
EAE was induced with spinal cord homogenate in complete Freund’s adjuvant on 
days 0 and 7, and a relapse induced on day 29. Animals were given 250 g/ml anti-
CD20 antibody on days 8 and 28 (Acute+Relapse group) or untreated (untreated 
group). The results represent the mean ± SEM daily score (n=8/9). 
Treatment 
Treatment 
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A 
Treatment Dose  
 
No. EAE/Total Max EAE Score 
±SEM 
Day of onset 
           ±SEM 
 
Untreated - 9/9 3.8 ± 0.3 16.6 ± 0.7 
Anti-CD20 250 g 8/10 3.8 ± 0.6 18.4 ± 1.7 
 
   B 
Treatment Dose  
 
No. EAE/Total Max EAE Score 
±SEM 
Day of onset 
±SEM 
 
Untreated - 7/7 3.8 ± 0.3 37.0 ± 2.4 
Anti-CD20 250 g 4/7 3.5 ± 0.4 36.5 ± 1.9 
 
Table 6.3: Treatment of relapsing remitting EAE with anti-CD20 antibody. 
EAE was induced with spinal cord homogenate in complete Freund’s adjuvant on 
days 0 and 7, and a relapse induced on days 29. Animals were given 250 g/mouse 
anti-CD20 antibody on day 8 and 28. The results represent the mean maximal score 
of animals that developed EAE and the day of onset of clinical signs in the acute 
phase (A) and in the relapse phase (B). 
 
6.2.6 Mitoxantrone and anti-CD4 antibody treatment alters EAE severity 
Mitoxantrone and anti-CD4 antibody were given as positive controls as they had 
previously been shown to alter the severity of EAE in the EAE model (Baker et al., 
1992; Pryce et al., 2005). Mitoxantrone and anti-CD4 antibodies were administered 
on day 8 pre-acute phase and both altered the severity of EAE in both the acute and 
the relapse phase (figure 6.8). There was a reduction on the number of animals 
with EAE in the mitoxantrone and anti-CD4 treated groups in comparison with the 
untreated group (table 6.4). A lengthening of the day of onset of disease was 
observed in the acute phase following anti-CD4 treatment.  
 
142 
 
5 10 15 20 25 30 35 40 45 50
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
Untreated
Anti-CD4
Mitoxantrone
 
Days post EAE induction
M
e
a
n
 C
li
n
ic
a
l 
s
c
o
r
e
 ±
 S
E
M
 
Figure 6.8: Treatment of relapsing remitting EAE with anti-CD4 antibody or 
mitoxantrone. EAE was induced with spinal cord homogenate in complete Freund’s 
adjuvant on days 0 and 7, and a relapse induced on days 29. Animals were given 
200 g/mouse anti-CD4 antibody or 2.5 mg/kg mitoxantrone on day 8. The results 
represent the mean ± SEM daily score. 
 
  
Treatment 
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A 
Treatment Dose No. EAE/Total Max EAE Score 
±SEM 
Day of onset 
±SEM 
 
Untreated - 8/10 3.9 ± 0.2 18.5 ± 1.9 
Anti-CD4 200 g 5/10 3.7 ± 0.3 21.8 ± 1.6 
Mitoxantrone 2.5 mg/kg 4/9 3.9 ± 0.3 18.8 ± 2.6 
   
B 
Treatment Dose No. EAE/Total Max EAE Score 
±SEM 
Day of onset 
±SEM 
 
Untreated - 8/10 3.8 ± 0.4 39.5 ± 1.5 
Anti-CD20 200 g 7/10 3.7 ± 0.5 40.9 ± 1.1 
Mitoxantrone 2.5 mg/kg 4/9 3.9 ± 0.3 41.8 ± 2.5 
     
Table 6.4: Treatment of relapsing remitting EAE with anti-CD4 antibody or 
mitoxantrone. EAE was induced with spinal cord homogenate in complete Freund’s 
adjuvant on days 0 and 7, and a relapse induced on days 29. Animals were given 
200 g/mouse anti-CD4 antibody or 2.5 mg/kg mitoxantrone on day 8. The results 
represent the mean maximal score of animals that developed EAE and the day of 
onset of clinical signs in the acute phase (A) and in the relapse phase (B). 
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6.3 Discussion 
EAE is thought to be a T cell mediated disease, but recent results from clinical trials 
and EAE studies has led to the re-examination of the function/importance of B cells 
in the pathogenesis of EAE and MS (Qin et al., 2001).  
 
This chapter details the effects of B cell depletion by anti-CD20 antibody 
administration on the severity of EAE. Initial studies investigated the depletion of B 
cells by administering anti-CD20 antibodies in naïve ABH mice. Intravenous 
administration of anti-CD20 in naïve mice led to significant reduction in B cells in 
the blood and a reduction in the spleen. 3 days post immunization showed the 
lowest levels of B cells in the blood and the levels were back up 2 weeks post 
immunization. As a result of the preliminary studies, anti-CD20 was administered at 
least 1-3 days before the onset of clinical disease to investigate the involvement of 
B cells in the development of clinical signs of EAE. In a spontaneous relapsing-
remitting EAE model, it was shown that depletion of B cells by administration of 
anti-CD20 antibody suppressed RR-EAE when treatment was started at a young age 
(Pollinger et al., 2009). Anti-CD4 depleting antibodies have been shown to prevent 
the development of EAE (O'Neill et al., 1993) and Mitoxantrone has also been shown 
to reduce severity and onset of EAE disease (Baker et al., 1992). Anti-CD20, anti-
CD4 and mitoxantrone were used in this study because they are the depleting 
strategies that were used in the NAbs model studied (discussed in chapters 4 and 
5). These were used to investigate their effect on the immune system in the EAE 
setting which is relevant to MS disease. 
 
Previous studies using different EAE models and different EAE induction methods 
have shown varying contradictory effects of anti-CD20 antibody administration on 
the disease. In a C57BL/6 human CD20 transgenic mouse model, it was observed 
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that administration of anti-CD20 before EAE induction with MOG35-55 or after onset 
of EAE led to increased disease severity (Weber et al., 2010). On the contrary in 
another study, it was observed that administration of anti-CD20 at the peak of EAE 
disease led to rapid recovery and reduced cumulative disease in the C57BL/6 mice 
(Matsushita et al., 2008). In the C57BL/6 mice, B cell depletion before EAE 
induction led to no change in disease onset but disease was more severe in these 
MOG35-55 EAE induced mice (Matsushita et al., 2008). When anti-CD20 antibody was 
administered in these mice before EAE onset, there was no change in disease as 
was observed in this study. In this study, anti-CD20 antibody was injected 
intravenously 1-3 days before the onset of clinical signs of EAE and there was no 
significant reduction in severity of the disease and also no significant effect on the 
onset of disease. On the other hand, in my project when anti-CD20 was given 
multiple times (pre-acute and pre-relapse, there was a modest reduction in the 
severity of relapse disease. This study shows that B cells were depleted by anti-
CD20 antibody and this may be important in the severity of EAE disease especially 
in the relapse phase of the disease in the Biozzi ABH model. Post relapse phase, the 
proportion of B cells in spleen in both the treated and untreated groups were 
similar, signifying that the B cell levels in the treated group had increased post 
depletion. 
This study supports the use of anti-CD20 depletion of activated B cells in the 
treatment of EAE and by extrapolation MS. Anti-CD20 depletes antibody generating 
B cells and these may be relevant in the neutralizing antibody model studied in 
chapter 3. Selective depletion of B cells may be a valuable strategy to further 
improve efficacy of B cell targeted therapies in MS and other inflammatory CNS 
demyelinating diseases.  
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Chapter 7 
7 General discussion and conclusions 
 
7.1 Key findings 
This project met the main aim to develop and establish a neutralizing antibody 
mouse model to recombinant human interferon beta (rhIFN). Initial studies 
involved 2 mouse models Biozzi ABH and BALB/c mice as potential NAbs models. 
Preliminary research showed that NAbs were more consistently detected in BALB/c 
mice than in ABH mice. The immunization protocol for establishing of NAbs was 
developed in the BALB/c mice using Betaferon®. RhIFN-specific T cell responses 
(proliferation and cytokine production) were observed in the established NAbs 
model. Depletion strategies were developed in naïve BALB/c mice, anti-CD4 and 
anti-CD20 antibodies significantly depleted CD4 T cells and B cells respectively in 
the blood and spleen following administration. Mitoxantrone induced toxicity in 
animals and so did not appear useful to examine the effects of Mitoxantrone in 
tolerance at the doses tested. These depletion strategies were used in conjunction 
with intravenous administration of rhIFN to induce tolerance in the NAbs model. 
I.v. administration of rhIFN in the NAbs model resulted in a reduction in the 
incidence of NAbs by 10-20%; the incidence of NAbs was further reduced in 
combination with depletion strategies. RhIFN-specific CD4 and CD8 T cell 
responses were reduced by the induction of tolerance in this project. 
 
BALB/c mice were used to develop the NAbs model in my project. The mice were 
immunized with recombinant human interferon beta (rhIFN) which is seen as a 
foreign protein by the mice. The amino acid sequences are different in human and 
in mice though there are many similar sequences within the protein. As a result of 
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the differences, the mice mounted an immune response to rhIFN when immunized 
with the protein. Neutralizing antibodies to the protein were detected, and antigen-
specific IFN production was also detected in my project. NAbs have previously been 
detected in BALB/c mice to cytomegalovirus (Fang et al., 2014), and to rhIFN 
(Rebif and Avonex) (Bellomi et al., 2007) using Rebif and Avonex. Antibodies to 
Betaferon has also previously been detected in BALB/c mice (Jiskoot et al., 2013).  
In my project Betaferon was used as this has previously been shown to be more 
immunogenic than the other 2 forms of rhIFNand NAbs to the protein were 
detected. The NAbs model was developed and used in studying tolerance induction 
to rhIFNA human IFN transgenic model was developed in the C57/BL6 mice to 
study tolerance (Hermeling et al., 2005). The mechanism of tolerance was by 
breaking of tolerance as the mice recognized rhIFN as a self-protein. In my project 
on the other hand, the mechanism of tolerance induction was the mice recognized 
rhIFNas a foreign protein. In preliminary studies, CD4 and D8 T cells mounted an 
antigen-specific response to rhIFNby cytokine production (IFN and IL17) as early 
as day 7. Further immunization led to an expansion of these effector cells. 
Proliferation of CD4 T cells were also enhanced by subcutaneous immunization with 
rhIFNInitial responders require a 2 signals to initiate a response but memory cells 
have been shown to require less stringent stimulation to initiate or sustain a 
memory response as was shown in in my project in the proliferation and IFN 
production observed in memory CD4 and CD8 T cell populations. 
Mitoxantrone, anti-CCD4 and anti-CD20 antibodies were the choice for the depletion 
strategy in my project as these have been trialed or are approved for the treatment 
of MS. Anti-CD4 and anti-CD20 antibodies significantly reduced CD4 T cells and B 
cells respectively in the spleen and blood in naive BALB/c mice. Mitoxantrone 
reduced CD4 T cells and B cells in the blood and significantly reduced CD4 and CD8 
T cells in the spleen, there was also a significant reduction in macrophages and 
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monocytes. Macrophages are microbicidal, antigen-presenting and cytokine- 
producing cells and play a crucial role in resistance to pathogens. These cells may 
play a role in development of disease (Sinha et al., 2008), as was observed in 
development of EAE symptoms in my project. There was a reduction in EAE 
symptoms in mice that were immunized with mitoxantrone (which significantly 
reduced monocytes and macrophages) in comparison with the control group that 
were not immunized. Macrophages as APCs could be involved in NAbs production, a 
reduction could lead to reduction in NAbs production. Due to the toxicity of 
mitoxantrone, this avenue could not be studied further in this project. 
Intravenous administration of antigen have been shown to induce tolerance. 
Induction of immune tolerance was successfully achieved in patients with 
hemophilia A with NAbs to recombinant factor VIII (FVIII) using repeated i.v. FVIII 
which resulted in reduction of NAbs in majority of patients (Astermark et al., 2006). 
Single i.v. IFN administration in MS patients with NAbs to the drug has been shown 
to decrease NAbs in the short-term (Millonig et al., 2009). However in a pilot study, 
continuous high-dose i.v. IFN did not appear to induce tolerance to IFN, but 
established its bioactivity in MS patients with high NAbs titres (Skrobald et al., 
2014). Tolerance has been induced in mice via the intravenous route of 
immunization. In my project, i.v. administration of rhIFN in naïve BALB/c mice led 
to induction of tolerance as observed by the reduction in CD4 T cell proliferation in 
response to the antigen. In established NAbs model, i.v. administration did not 
appear to affect the outcome of NAbs incidence. It is most likely that prior 
immunization with rhIFNresults in the development of mature rhIFN-specific B 
cell and intravenous administration of rhIFN leads to relocation of the antigen to 
the spleen where the primed B cells can rapidly respond. In a mouse model, it was 
observed that single administration of rhIFN led to NAbs production and i.v. 
administration led to increased levels of NAbs which suggest a booster effect on 
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primed cells as observed after vaccine administration (Kijanka et al., 2013). The 
route of administration of antigen is vital in determining the response observed. It is 
believed that subcutaneous administration is the most immunogenic and i.v. is the 
least immunogenic. However, it has been observed in some studies that i.v. 
administration of anti-TNF for instance is more immunogenic when injected i.v. 
than when administered subcut in the cynomolgus monkey (Emery 2003). In my 
project i.v. administration of IFN in naïve BALB/c led to reduced NAbs incidence. 
 
 
7.2 Value of the NAbs mouse model 
The NAbs mouse model is a valuable model for studying different strategies for 
induction of tolerance to rhIFN. The main advantage of the NAbs model is that the 
mechanism of NAbs induction is similar to that observed in IFN-treated MS patients 
with NAbs; IFN is seen as a foreign protein and an immune response is mounted. 
This model can also be used to study aspects of NAbs development, elimination and 
control. 
 
Preliminary immunization protocols showed that NAbs was induced and was 
observed with an incidence 50-70% after day 35. RhIFN-specific CD4 and CD8 T 
cells proliferative responses were also observed in this model. Once NAbs was 
established in this model, then tolerization strategies were investigated and 
developed in the model and NAbs incidence and CD4/CD8 T cell responses were 
used as indicators for tolerance induction. In this model, intravenous administration 
of rhIFN in the NAbs model led to a reduction in the incidence of NAbs and also a 
reduction in CD4/CD8 T cell responses to the protein. Depleting cells prior to 
tolerance induction further reduced the incidence of NAbs. The NAbs mouse model 
do not show any physical signs once NAbs has been induced and this is an 
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advantage over the EAE model (mouse model for MS) where neurological signs are 
observed. The results observed shows that the NAbs model could potentially be 
used to investigate and develop a better understanding of NAbs development and 
tolerance induction strategies. 
 
As a mouse model, there are limitations that need to be looked at closely. The most 
significant limitation of the model is incidence of NAbs which is between 50-70%, 
therefore reducing the number available for each study. To overcome this limitation, 
the immunization protocol can be further developed to increase the incidence of 
NAbs in the mouse model. In this project different immunization schedules were 
investigated and the best one used for the project which involved immunizing sub-
cut on days 0, 7 and 21 with 20 g Betaferon in CFA. Other rhIFN formulation 
could also be used in developing the immunization strategy. Another strategy could 
be the use of other bacteria within the CFA to boost the response to IFN. Another 
weakness is the volume of samples that can be obtained from these animals at any 
time point. Due to the small volume of blood or plasma obtained, the development 
of assays and the number of assay used for investigating tolerance induction was 
limited. One way to overcome this would be to pool samples in groups and thereby 
increasing sample volumes. 
 
NAbs in the context of IFN (NAbs model) was chosen rather than MS directly. 
Establishing of the NAbs mouse model has several implications for work in the field 
of research into neutralizing antibodies in MS patients with NAbs to IFN. The 
mechanism of NAbs development in both the model and in MS patients are similar, 
it is hoped that strategies used in the NAbs model can be extrapolated for use in MS 
patients. Intravenous administration of IFN in combination with depletion 
strategies reduced the incidence of NAbs in this model, and further methods of 
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tolerance induction can be investigated in this model. NAbs to IFN in MS patients 
have been shown to reduce the bioavailability of the drug (Francis et al., 2005); 
induction of tolerance to IFN would therefore help in eliminating NAbs and 
increasing the bioavailability of the drug. 
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7.3 Future work 
 
Chapter 3: Establishing of NAbs model. 
(a) Further develop the immunization schedule (including use of different IFN 
formulations) in the NAbs model to increase the incidence of NAbs.  
(b) Investigate the development of a NAbs model in larger animals such as the 
rat, to increase sample volumes for assay development, optimization and analysis. 
 
Chapter 4: Development of depletion strategies 
(a) Investigate the use of other available depleting antibodies in the NAbs 
model, including anti-CD52 (alemtuzumab) and anti-CD19 antibodies. 
 
Chapter 5: Development of tolerization strategy 
(a) Further develop the induction of tolerance by intravenous rhIFN, the volume 
to be used and the timings for re-introduction of the protein. 
 
Chapter 6: EAE and depletion strategy 
(a) The depletion strategies to be developed in chapter 4 above (anti-CD52 and 
anti-CD19) can be tested in the EAE model. 
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7.4 Conclusions  
This project successfully met the aim to develop a neutralizing antibody “NAbs” 
mouse model against recombinant human interferon beta for the study of tolerance 
induction strategies, which is relevant for IFN-treated multiple sclerosis patients 
that have developed neutralizing antibodies.  
1. Neutralizing antibodies were successfully developed in the BALB/c mice. An 
immunization protocol was developed and refined resulting in more consistent 
establishment of NAbs to rhIFN. 
 
2. Depletion strategies using CD4+ and CD20+ depleting antibodies and 
mitoxantrone successfully deleted cell subsets in naïve BALB/c mice. 
 
3. Tolerance successfully induced in NAbs model by intravenous administration 
of rhIFN. 
 
4. Tolerance enhanced by depletion of cell groups prior to intravenous re-
introduction of rhIFN being the best strategy. 
 
5. Depletion strategies employed in the EAE setting successfully reduced the 
incidence of EAE. 
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